Exhibition Guide

General Poster Session
More than 90 posters will be presented.

Featuring

NCCN Reimbursement Resource Room
Visit and learn about reimbursement help and services available.

Health Information Technology Row
Visit and learn how HIT tools use NCCN Content to assist oncology practices.

NCCN Patient Advocacy Pavilion
Visit patient advocacy kiosks representing a range of disease types.

Exhibitor Showcase Presentations
Hear about new products and programs in oncology.

NCCN Trends™ Survey Kiosks & NCCN Exhibitor Passport
Complete the Trends™ Surveys or an Exhibitor Passport to receive a free gift.

Cyber Cafe
Sponsored by Bristol-Myers Squibb.

Print Session Presentations at Your Convenience
Self-serve printing stations are located outside of the General Session Room, Gatlin D & E.

EXHIBITION HALL LOCATION
GATLIN B & C

EXHIBITION HALL HOURS
THURSDAY, MARCH 23
7:00 AM – 3:40 PM
5:30 – 7:30 PM
(Welcome Reception)
FRIDAY, MARCH 24
7:00 AM – 3:40 PM

CONFERENCE APP
Password: conference17

EXHIBITION HALL LOCATION
GATLIN B & C

EXHIBITION HALL HOURS
THURSDAY, MARCH 23
7:00 AM – 3:40 PM
5:30 – 7:30 PM
(Welcome Reception)
FRIDAY, MARCH 24
7:00 AM – 3:40 PM

CONFERENCE APP
Password: conference17

Orlando, Florida
March 23–25, 2017
<table>
<thead>
<tr>
<th>Level Sponsor</th>
<th>Companies</th>
</tr>
</thead>
<tbody>
<tr>
<td>Presenting</td>
<td>Eisai Inc.</td>
</tr>
<tr>
<td>Platinum</td>
<td>Bristol-Myers Squibb, Incyte Corporation, TESARO</td>
</tr>
<tr>
<td>Gold</td>
<td>EMD Serono, Inc., Janssen Oncology, a Pharmaceutical Company of Johnson &amp; Johnson, Shire</td>
</tr>
<tr>
<td>Silver</td>
<td>AbbVie</td>
</tr>
<tr>
<td>Bronze</td>
<td>AstraZeneca, Celgene Corporation, Helsinn, Jazz Pharmaceuticals, Inc., Pharmacysllcs LLC, an AbbVie Company, Teva Oncology</td>
</tr>
</tbody>
</table>
### NCCN Patient Advocacy Pavilion Sponsors

<table>
<thead>
<tr>
<th>Diamond</th>
<th>Eisai Inc.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ruby</td>
<td>Celgene Corporation</td>
</tr>
<tr>
<td></td>
<td>Lilly Oncology</td>
</tr>
<tr>
<td></td>
<td>Pharmacyclics LLC, an AbbVie Company</td>
</tr>
<tr>
<td></td>
<td>Takeda Oncology</td>
</tr>
<tr>
<td>Emerald</td>
<td>AstraZeneca</td>
</tr>
<tr>
<td></td>
<td>Dendreon</td>
</tr>
<tr>
<td></td>
<td>Genentech</td>
</tr>
<tr>
<td></td>
<td>Genoptix</td>
</tr>
<tr>
<td></td>
<td>Gilead Sciences, Inc.</td>
</tr>
<tr>
<td></td>
<td>Heron Therapeutics</td>
</tr>
<tr>
<td></td>
<td>Incyte Corporation</td>
</tr>
<tr>
<td>Topaz</td>
<td>AmerisourceBergen</td>
</tr>
<tr>
<td></td>
<td>enterade®</td>
</tr>
</tbody>
</table>

### An NCCN Roundtable Discussion

**Emerging Issues in Oncology – Addressing Health Disparities in Cancer Care from Diagnosis to Survivorship**

**This roundtable is supported by:**
- An educational grant from Agios
- An educational donation provided by Amgen
- Astellas
- An unrestricted grant from Eisai Inc.
- Janssen Oncology, a Pharmaceutical Company of Johnson & Johnson
- A contribution from Lilly
- Pharmacyclics LLC, an AbbVie Company, and Janssen Biotech
- Taiho Oncology
- An educational grant from Takeda Oncology

**This roundtable is sponsored by:**
- AbbVie
- A financial contribution from Bristol-Myers Squibb
- Novartis
## Exhibitor Showcase Presentation Schedule*

### Thursday, March 23, 2017

**7:00 – 7:30 AM**  
Targeting the JAK Pathway in Patients Whose Polycythemia Vera Is Not Well Controlled on Hydroxyurea  
*Presented by Incyte Corporation*

### Friday, March 24, 2017

**7:00 – 7:30 AM**  
Disease Progression and Current Challenges in ALK-Positive NSCLC  
Mark A. Socinski, MD  
Executive Medical Director  
Florida Hospital Cancer Institute  
Orlando, Florida  
*Presented by ARIAD Pharmaceuticals, Inc.*

### Thursday, March 23, 2017

**7:30 – 8:00 AM**  
Immuno-Oncology in Urothelial Carcinoma  
*Presented by AstraZeneca*

**9:35 – 9:45 AM**  
Introducing the NCCN Radiation Therapy Compendium™  
*Presented by NCCN*

**12:30 – 1:00 PM**  
A Microtubule Inhibitor Alters Tumor Microenvironment and Decreases Invasion and Migration  
Dr. Fernando de Zarraga  
Advanced Medical Specialties  
*Presented by Eisai Inc.*

**1:00 – 1:30 PM**  
Hormone Refractory Metastatic Prostate Cancer: An Individualized Approach to Patient Management  
*Presented by Sanofi Genzyme*

**3:15 – 3:40 PM**  
**JNCCN 360 — A new JNCCN and NCCN initiative**  
*Presented by Harborside Press*

### Friday, March 24, 2017

**7:30 – 8:00 AM**  
IMBRUVICA® (ibrutinib) with a focus on CLL/SLL and relapsed/refractory MZL  
*Presented by Pharmacyclics LLC, an AbbVie company, and Janssen Biotech, Inc.*

**9:35 – 9:45 AM**  
Introducing the NCCN Radiation Therapy Compendium™  
*Presented by NCCN*

**12:30 – 1:00 PM**  
LONSURF® for the Treatment of Refractory Metastatic Colorectal Cancer  
*Presented by Taiho Oncology, Inc.*

**1:00 – 1:30 PM**  
Emerging Strategies for the Management of HR+/HER2- Advanced or Metastatic Breast Cancer  
*Presented by Novartis*

* Seating is open for all conference attendees in the Exhibitor Showcase area in the center of the NCCN Exhibition Hall.  
No pre-registration required.
At AbbVie, we build bonds with oncologists, patients, payers, advocacy groups, health authorities, and other pharmaceutical companies, because we know that advancing the science of this devastating disease is not something that one person, or even one company, can do alone.

Together we can conduct research that deepens our understanding of the disease and its pathways, to ultimately develop new molecules that make a transformational improvement in cancer care.

LEARN MORE ABOUT THE BONDS WE’RE BUILDING AT BOOTH 634.

NCCN recognizes

Bristol-Myers Squibb

for sponsorship of the Cyber Café
Reimbursement Resource Room Participants

Astellas Pharma US, Inc. XTANDI Support Solutions .................................... # R2
AstraZeneca Access 360™ .................................................................. # R3
Boehringer Ingelheim Solutions Plus™ ............................................ # R4
Eisai Assistance Program (EAP) ....................................................... # R6
Genentech Access Solutions ........................................................... # R7
Genoptix, Inc., a Novartis Company .................................................. # R8
IncyteCARES (Incyte Corporation) .................................................... # R10
Ipsen ......................................................................................... # R11
Lilly PatientOne: Reimbursement & Patient Assistance Programs ................. # R16
NanoString Technology .................................................................. # R16
The Prosinga Patient Support Program ............................................ # R12
Novartis Oncology - Patient Assistance NOW Oncology (PANO) .... # R13
Patient Access Network (PAN) Foundation ........................................ # R9
Sandoz One Source™: Patient Support Services .................................. # R14
Taiho Oncology Patient Support ..................................................... # R15

Exhibitors

AbbVie .................................................. # 702
AbbVie Inc. .................................................. # 634
Agendia Inc. .................................................. # 624
American Society of Clinical Oncology (ASCO) ................................ # 120
Amgen ...................................................................................... # 231
APOBIOLIGIX .............................................................................. # 210
ARIAD Pharmaceuticals, Inc. ......................................................... # 312
Astellas/Medivation ...................................................................... # 703
AstraZeneca .................................................................................. # 525
Bayer ......................................................................................... # 627
BTG ............................................................................................... # 510
Celgene Corporation ....................................................................... # 602
Clovis Oncology ............................................................................ # 339
Cumberland Pharmaceuticals .......................................................... # 625
Eisai Inc. ........................................................................................ # 436
enterade* ..................................................................................... # 612
Exelixis, Inc. ................................................................................... # 315
Feel Good, Inc. ................................................................................ # 618
GE Healthcare ................................................................................ # 230
Genentech Inc. ............................................................................... # 632
Genentech USA, Inc. ....................................................................... # 206
Genomic Health, Inc. ..................................................................... # 207
Genoptix Medical Laboratory ......................................................... # 202
GenPath Oncology .......................................................................... # 223
Gilead Sciences .............................................................................. # 203
Harsborel Press ................................................................................ # 122
Helsinn ........................................................................................... # 529
Heron Therapeutics, Inc. ................................................................. # 118
Incyte Corporation ........................................................................... # 342
INSYS Therapeutics ......................................................................... # 314
Ipsen .............................................................................................. # 209
Janssen Biotech, Inc. ........................................................................ # 605
Jazz Pharmaceuticals, Inc. ................................................................. # 228
Leadiant Biosciences, Inc. ................................................................. # 603
LeanTaaS ........................................................................................ # 115
Merck & Co., Inc. ........................................................................... # 226 & # 704
Merck KGaA/Pfizer .......................................................................... # 114
*Moffitt Cancer Center ................................................................. # 418
NCCN .............................................................................................. # 422
NCCN Continuing Education......................................................... # 424
NCCN Foundation ........................................................................... # 424
NCCN Oncology Research Program .......................................... # 333
NCCN Poster Session ................................................................. # 102
NeoGenomics .................................................................................. # 711
Novartis .......................................................................................... # 232 & # 302
Novocure, Inc. .................................................................................. # 432
Oncology Nursing Certification Corporation .................................... # 611
Personal Genome Diagnostics ....................................................... # 117
Pfizer ............................................................................................... # 520
Prometheus Laboratories Inc. .......................................................... # 429
Sanofi Genzyme ............................................................................. # 528
Seattle Genetics ................................................................................ # 531
Sheridan Healthcare .......................................................................... # 412
Shire ............................................................................................... # 201
Siemens Healthineers ...................................................................... # 512
Spectrum .......................................................................................... # 610
St. Peter’s Hospital ........................................................................... # 717
Sun Pharmaceutical Industries, Inc. .................................................. # 709
Taiho Oncology, Inc. ......................................................................... # 530
Takeda Oncology ............................................................................. # 205
TESARO ......................................................................................... # 532
Teva Oncology .................................................................................. # 630

Health Information Technology Row

Carevive Systems ............................................................................. # 220
eviCore healthcare ........................................................................... # 106
IBM Watson Health ........................................................................... # 332
McKesson Specialty Health ............................................................... # 321
MedCurrent ..................................................................................... # 219
NantHealth, Inc. ................................................................................ # 218
National Decision Support Company ............................................. # 107
Navigating Cancer ............................................................................ # 104
New Century Health, Inc. ................................................................. # 105
NCCN-Flatiron Quality & Outcomes Database ................................... # 420
Univadis ........................................................................................... # 320

Patient Advocacy Pavilion

Aplastic Anemia and MDS International Foundation ......................... # A13
BAG IT ............................................................................................... # A15
Cancer Hope Network ....................................................................... # A1
Colon Cancer Alliance ...................................................................... # A2
Family Reach ..................................................................................... # A3
Fight Colorectal Cancer .................................................................... # A4
Kidney Cancer Association .............................................................. # A5
Live By Living .................................................................................... # A6
Living Beyond Breast Cancer (LBBC) ................................................ # A7
Lung Cancer Alliance ........................................................................ # A8
Lung Cancer Research Council ......................................................... # A17
LUNGevity Foundation ..................................................................... # A9
Mesothelioma Applied Research Foundation ................................ # A16
MPN Research Foundation ............................................................... # A10
RN Cancer Guides Solutions ............................................................ # A11
SHARE Cancer Support ................................................................. # A14
The Leukemia & Lymphoma Society ................................................ # A12
ThyCa: Thyroid Cancer Survivors’ Association, Inc. ...................... # A18
A Microtubule Inhibitor
Alters Tumor Microenvironment and
Decreases Invasion and Migration*

Thursday, March 23, 2017
Rosen Shingle Creek
Orlando, Florida
Location: Exhibitor Showcase, NCCN Exhibition Hall
Presentation:
12:30 PM - 1:00 PM

Fernando I. de Zarraga, Jr., MD
Advanced Medical Specialties
Miami, Florida

Preclinical evidence does not imply clinical efficacy.

Indication
HALAVEN is a microtubule inhibitor indicated for the treatment of patients with
• metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease.
  Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting
• unresectable or metastatic liposarcoma who have received a prior anthracycline-containing regimen

Important Safety Information for HALAVEN® (eribulin mesylate)

Warnings and Precautions
Neutropenia: Severe neutropenia (ANC <500/mm³) lasting >1 week occurred in 12% of patients with mBC and liposarcoma or leiomyosarcoma. Febrile neutropenia occurred in 5% of patients with mBC and 2 patients (0.4%) died from complications. Febrile neutropenia occurred in 0.9% of patients with liposarcoma or leiomyosarcoma, and fatal neutropenic sepsis occurred in 0.9% of patients. Patients with mBC with elevated liver enzymes >3 × ULN and bilirubin >1.5 × ULN experienced a higher incidence of Grade 4 neutropenia and febrile neutropenia than patients with normal levels. Monitor complete blood cell counts prior to each dose, and increase the frequency of monitoring in patients who develop Grade 3 or 4 cytopenias. Delay administration and reduce subsequent doses in patients who experience febrile neutropenia or Grade 4 neutropenia lasting >7 days.

Please see additional Important Safety Information on reverse side.

Disclaimer
This invitation is intended for the recipient only; spouses or other guests are not permitted to attend. This promotional event is sponsored by Eisai. The information being presented by the speaker is consistent with the FDA guidelines.
This is a promotional presentation discussing a pharmacological treatment option.

Speaker Program Guidelines
Vermont law prohibits, Minnesota law restricts, and Department of Veterans Affairs and Department of Defense policy prohibits Eisai from offering meals at speaker events to certain health care professionals. If you are licensed in either of those states, or employed by either agency, Eisai regrets that due to these restrictions, we will not be able to offer a meal in conjunction with this event. Additionally, Eisai is required by Massachusetts, Vermont, Washington, DC, the Federal Physician Payment Sunshine Act, and European Federation of Pharmaceutical Industries and Associations (EFPIA) codes to disclose certain value transfers, eg, meals, provided to certain health care professionals. If you have questions regarding how Eisai tracks and reports this information, please contact Eisai at 1-855-643-4328.

© 2017 Eisai Inc. All rights reserved. Printed in USA/February 2017  HALA-US0657
Important Safety Information for HALAVEN® (eribulin mesylate) (continued)

Warnings and Precautions (continued)

Peripheral Neuropathy: Grade 3 peripheral neuropathy occurred in 8% of patients with mBC (Grade 4=0.4%) and 22% developed a new or worsening neuropathy that had not recovered within a median follow-up duration of 269 days (range 25-662 days). Neuropathy lasting >1 year occurred in 5% of patients with mBC. Grade 3 peripheral neuropathy occurred in 3.1% of patients with liposarcoma and leiomyosarcoma receiving HALAVEN and neuropathy lasting more than 60 days occurred in 58% (38/65) of patients who had neuropathy at the last treatment visit. Patients should be monitored for signs of peripheral motor and sensory neuropathy. Withhold HALAVEN in patients who experience Grade 3 or 4 peripheral neuropathy until resolution to Grade 2 or less.

Embryo-Fetal Toxicity: HALAVEN can cause fetal harm when administered to a pregnant woman. Advise females of reproductive potential to use effective contraception during treatment with HALAVEN and for at least 2 weeks following the final dose. Advise males with female partners of reproductive potential to use effective contraception during treatment with HALAVEN and for 3.5 months following the final dose.

QT Prolongation: Monitor for prolonged QT intervals in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, and electrolyte abnormalities. Correct hypokalemia or hypomagnesemia prior to initiating HALAVEN and monitor these electrolytes periodically during therapy. Avoid in patients with congenital long QT syndrome.

Adverse Reactions
In patients with mBC receiving HALAVEN, the most common adverse reactions (≥25%) were neutropenia (82%), anemia (58%), asthenia/fatigue (54%), alopecia (45%), peripheral neuropathy (35%), nausea (35%), and constipation (25%). Febrile neutropenia (4%) and neutropenia (2%) were the most common serious adverse reactions. The most common adverse reaction resulting in discontinuation was peripheral neuropathy (5%).

In patients with liposarcoma and leiomyosarcoma receiving HALAVEN, the most common adverse reactions (≥25%) reported in patients receiving HALAVEN were fatigue (62%), nausea (41%), alopecia (35%), constipation (32%), peripheral neuropathy (29%), abdominal pain (29%), and pyrexia (28%). The most common (≥5%) Grade 3-4 laboratory abnormalities reported in patients receiving HALAVEN were neutropenia (32%), hypokalemia (5.4%), and hypocalcemia (5%). Neutropenia (4.9%) and pyrexia (4.5%) were the most common serious adverse reactions. The most common adverse reactions resulting in discontinuation were fatigue and thrombocytopenia (0.9% each).

Use in Specific Populations

Lactation: Because of the potential for serious adverse reactions in breastfed infants from eribulin mesylate, advise women not to breastfeed during treatment with HALAVEN and for 2 weeks after the final dose.

Hepatic and Renal Impairment: A reduction in starting dose is recommended for patients with mild or moderate hepatic impairment and/or moderate or severe renal impairment.
At Bristol-Myers Squibb, we are working together for patients. Our mission is clear — we discover, develop and deliver innovative medicines that help people prevail over serious diseases. And our sense of urgency is real — we work every day in every part of our company to make a meaningful difference in the lives of patients.

**It’s what we do. It’s why we do it.**

Visit [www.bms.com](http://www.bms.com) to learn more.
VISIT THE MERCK BOOTH TO LEARN MORE ABOUT KEYTRUDA:

• Approved indications

• Resources for health care professionals

• The Merck Access Program

• KEY+YOU Support Program for patients
we Measure our success in your tomorrows

Learn more about our commitment to cancer care at emdserono.com.
What science can do

**Oncology combination therapies**
AstraZeneca is investigating combinations of biologic and small-molecule therapies for the treatment of cancer. These combinations target the tumor directly and some help boost the body’s own immune system to potentially induce cell death.

**AstraZeneca is proud to support**
The National Comprehensive Cancer Network

For more information, please visit astrazeneca-us.com
At Helsinn, we are delivering more treatments to lift the burden of cancer and investing in research to meet the needs of patients, for better tomorrows.

www.Helsinn.com

Going further to bring better todays to even more people with cancer

LOWER WAIT TIMES THROUGH OPTIMIZED INFUSION SCHEDULING

www.leantaas.com

TRUSTED BY 50+
OF THE NATION’S LEADING CANCER CENTERS
For more than 25 years, Gilead has worked to develop medicines that address areas of unmet medical need for people around the world.

Our portfolio of medicines and pipeline of investigational drugs include treatments for HIV/AIDS, liver diseases, cancer, inflammatory and respiratory diseases, and cardiovascular conditions.

Every day we strive to transform and simplify care for people with life-threatening illnesses.

GILEAD IS PROUD TO SUPPORT THE NCCN 22ND ANNUAL CONFERENCE.
A partial list of amazing things Greg can do.

Amazing because in 2004, Greg was diagnosed with inoperable lung cancer and given one year to live.

Years later, he’s alive and well thanks to breakthrough targeted cancer therapy from the Mass General Cancer Center. And now, for Greg and others like him, every day is an amazing day.
### Health Information Technology Row

<table>
<thead>
<tr>
<th>Company</th>
<th>Exhibit Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>Carevive Systems</td>
<td>220</td>
</tr>
<tr>
<td>eviCore healthcare</td>
<td>106</td>
</tr>
<tr>
<td>IBM Watson Health</td>
<td>332</td>
</tr>
<tr>
<td>McKesson Specialty Health</td>
<td>321</td>
</tr>
<tr>
<td>MedCurrent</td>
<td>219</td>
</tr>
<tr>
<td>NantHealth, Inc.</td>
<td>218</td>
</tr>
<tr>
<td>National Decision Support Company</td>
<td>107</td>
</tr>
<tr>
<td>Navigating Cancer</td>
<td>104</td>
</tr>
<tr>
<td>New Century Health, Inc.</td>
<td>105</td>
</tr>
<tr>
<td>NCCN-Flatiron Quality &amp; Outcomes Database</td>
<td>420</td>
</tr>
<tr>
<td>Univadis</td>
<td>320</td>
</tr>
</tbody>
</table>

**Carevive Systems # 220**
Carevive provides personalized and dynamic cancer care plans for patients that improve clinical outcomes and enable oncology practices to operate in emerging value-based models. Our care plans continuously update to provide ongoing guidance to patients based on their experiences throughout the journey. This process allows us to collect longitudinal Real-World Evidence (RWE) on the cancer patient experience that will drive better care delivery and oncolytic drug use and future development.

**eviCore healthcare # 106**
eviCore healthcare (eviCore) is a medical benefits management (MBM) company committed to making a positive impact on improving the financial health of our customers. Through innovative clinical, research, business and operational solutions, facilitated by integrated technology systems, we focus on improving the financial health of our customers so they may provide the best care to their patients. For more information, visit [www.evicore.com](http://www.evicore.com)

**IBM Watson Health # 332**
At IBM Watson Health, we are working to support those fighting against cancer by helping to improve the ability of doctors, researchers and insurers to transform care through knowledge. From research to treatment, cognitive computing can help physicians transform healthcare for the more than 1.6 million Americans who develop cancer annually and the nearly 14 million currently fighting it by helping to redefine how clinical trials are conducted, treatments are considered and care is personalized. Visit [www.ibm.com/watsonhealth](http://www.ibm.com/watsonhealth).

**McKesson Specialty Health # 321**
McKesson Specialty Health, a division of McKesson Corporation, empowers the community patient care delivery system by helping community practices advance the science, technology and quality of care. Through innovative clinical, research, business and operational solutions, facilitated by integrated technology systems, we focus on improving the financial health of our customers so they may provide the best care to their patients. For more information, visit [www.mckessonspecialtyhealth.com](http://www.mckessonspecialtyhealth.com)

**MedCurrent # 219**
MedCurrent is a physician-founded Clinical Decision Support (CDS) company focused on three core operating principles: improved patient outcomes, lower system healthcare costs, and better patient experiences. Centered on a deep EMR integration philosophy, our technology platform streamlines provider ordering by merging evidence-based guidelines with clinical workflows at the point of care. Ease-of-use, configurability, and enterprise scalability make MedCurrent a global leader in CDS solutions.

**NantHealth, Inc. # 218**
NantHealth, Inc., a member of the NantWorks ecosystem of companies, is a next-generation, evidence-based, personalized healthcare company enabling improved patient outcomes and more effective treatment decisions for critical illnesses. NantHealth’s unique systems-based approach to personalized healthcare applies novel diagnostics tailored to the specific molecular profiles of patient tissues and integrates this molecular data in a clinical setting with large-scale, real-time biometric signal and phenotypic data to track patient outcomes and deliver precision medicine. For nearly a decade, NantHealth has developed an adaptive learning system, CLINICS, which includes its unique software, middleware and hardware systems infrastructure that collects, indexes, analyzes and interprets billions of molecular, clinical, operational and financial data points derived from novel and traditional sources, continuously improves decision-making and further optimizes our clinical pathways and decision algorithms over time. For more information please visit [www.nanhealth.com](http://www.nanhealth.com) and follow Dr. Soon-Shiong on Twitter @DrPatSoonShiong.

**National Decision Support Company # 107**
National Decision Support Company enables stakeholders in the healthcare delivery process to deliver more efficient and appropriate care, improve population health, and save money. Variations and gaps in care delivery cost providers and patients billions of dollars annually and result in life threatening medical errors. NDSC’s CareSelect decision support platform enables the transition to value based care & payment models and risk sharing payment models while reducing inconsistencies in patient care. The CareSelect platform converts published guidelines from credible, compliant content sources-covering diagnostic imaging, medication, lab and care pathways-into actionable decision support criteria delivered directly into the EMR workflow.

**Navigating Cancer # 104**
Navigating Cancer is the pioneer in patient relationship management software for cancer care. This patient-centered oncology platform puts the patient at the center of their own care and enables the care team to provide coordinated and comprehensive care at a lower cost. With industry proven patient satisfaction ratings, the platform enables providers to gain efficiencies in their care, meet value-based care initiatives, improve medication adherence and reduce hospitalizations for cancer patients.

**New Century Health, Inc. # 105**
New Century Health (NCH) is the national leader in helping patients with cancer receive the highest quality, cost-effective treatments. NCH partners with Oncology Practices, Accountable Care Organizations and Patient Centered Medical Homes in using value-based oncology management solutions. Our suite of clinical, analytical and support services enables practices to deliver evidence-based care using a total cost-of-care management approach to millions of Medicare, Commercial and Medicaid members.

**NCCN-Flatiron Quality & Outcomes Database # 420**
Flatiron Health is a healthcare technology company that’s radically transforming cancer treatment. Our mission is to organize the world’s oncology data to make it actionable for providers, patients, researchers and life science companies. Flatiron’s technology aggregates millions of patient clinical records, and then analyzes the information to provide new and unseen insights for doctors, researchers and scientists. We believe that learning from “real-world” patient evidence is the key to dramatically improving treatment outcomes. Flatiron works with over 250 U.S. cancer clinics, tracking over 1.5 million patients. Please visit [http://flatiron.com](http://flatiron.com) for more information.

**Univadis # 320**
Univadis identifies and summarizes the clinical and professional news updates most important to you and your practice. Univadis experts scan hundreds of peer-reviewed studies each day – distilling only the most relevant news into concise, bulleted summaries formatted for instant understanding of key takeaways, results, and impact on your daily practice.
Patient Advocacy Pavilion

Aplastic Anemia and MDS International Foundation # A13
The Aplastic Anemia and MDS International Foundation (AAMDSIF) supports, connects and educates patients, caregivers and health professionals on bone marrow failure diseases, including aplastic anemia, MDS, PNH and related diseases. Its mission is to serve its community in every cycle of these diseases worldwide. That includes providing the vital information and resources needed to adjust to the initial life-altering phase of diagnosis, the potentially life-threatening treatment phase and the life-long phase of having a chronic disease. AAMDSIF also promotes and invests in collaborative clinical research to accelerate the discovery of better treatments and cures for bone marrow failure diseases.

BAG IT # A15
BAG IT, a non-profit organization, supports people with any cancer and their families with information to help them cope with the challenges associated with diagnosis and treatment and encourage them to become an active part of their care team. BAG IT resources include publications from NCI, a patient navigation binder, and a pre-loaded 4-GB USB wristband with resources and space to store personal medical information. BAG IT is distributed by medical providers and assists them to meet accreditation guidelines for patient education. BAG IT helps Fight the Fear. For more information, go to bagit4u.org; contact information: Sherri Romanoski, Director/Founder, sherr@bagit4u.org; 520.575.9602.

Cancer Hope Network # A1
Cancer Hope Network provides free one-on-one support to adult cancer patients and their loved ones. Each of CHN’s 400 volunteers is at least one year post-treatment or successfully undergoing maintenance therapies. They offer support from diagnosis, through treatment and into recovery. Cancer Hope Network serves cancer patients in the United States and Canada.

Colon Cancer Alliance # A2
The Colon Cancer Alliance was founded in 1999 by a group of 41 survivors, caregivers, and friends who saw the need to educate the public about colon cancer and provide support to those affected by the disease. Since then, our organization has grown to be the nation’s oldest and largest nonprofit dedicated to the disease, helping nearly 1.5 million patients and families every year. The Colon Cancer Alliance’s mission is simple: to knock colon cancer out of the top three cancer killers. We are doing this by championing prevention, funding cutting-edge research, and providing the highest quality patient support services. info@ccalliance.org, www.ccalliance.org, Helpline (877) 422-2030.

Family Reach # A3
Family Reach is a financial lifeline for families fighting cancer. For over two decades, Family Reach has helped families with cancer manage the overwhelming financial and emotional barriers of the disease. Working in close collaboration with a network of more than 165 cancer centers nationwide, Family Reach provides immediate financial assistance, education and outreach to families in need. To learn more, visit www.familyreach.org.

Fight Colorectal Cancer # A4
Fight Colorectal Cancer is a national nonprofit leading the way when it comes to advocacy and awareness in colorectal cancer. We empower and activate a community of patients, fighters and champions to push for better policies and to supportresearch, and education and awareness for all those touched by colorectal cancer. Check out all of the ways to get involved at www.fightCRC.org and follow us on social media @FightCRC.

Kidney Cancer Association # A5
The Kidney Cancer Association (KCA), a charitable organization made up of patients, family members, physicians, researchers, and other health professionals from around the world. It is the world’s first international charity dedicated specifically to the eradication of death and suffering from renal cancers. It is also the largest kidney cancer charity, with members in more than 100 countries.

Live By Living # A6
Live by Living is a 501(c)(3) that connects cancer survivors and caregivers with nature and one another through walks in the park, day hikes, and weekend retreats in the Colorado Rockies.

Living Beyond Breast Cancer (LBCC) # A7
Living Beyond Breast Cancer (LBBC), founded in 1991, is a nonprofit organization whose mission is to connect people with trusted information and a community of support. LBBC provides support and education for individuals throughout the country who are impacted by breast cancer. LBBC reaches more than 540,000 people annually through our website, publications, educational programs, website, social media, and Breast Cancer Helpline. For more information, please go to LBBC.org.

Lung Cancer Alliance # A8
Lung Cancer Alliance is the leading and highest rated nonprofit organization dedicated to fighting lung cancer in the nation. Since 1995, we have played a critical role in every major advance – changing how we support, talk about, detect, and treat the disease – and turning those impacted into survivors. Our mission is saving lives and advancing research by empowering those living with and at risk for lung cancer. www.lungcanceralliance.org.

Lung Cancer Research Council # A17
The mission of the Lung Cancer Research Council is to increase awareness about lung cancer and to promote early detection and screening of lung cancer to extend and save lives. Along with Millennium Physicians Group, Moffitt Cancer Center and Florida Cancer Specialists, LCRC is organizing a lung cancer screening trial in SW Florida. The goal of the trial is to provide research data on the efficacy of screening in a demographic area outside a major cancer center using a primary care physician’s group to accrue and follow patients. lungcancerresearchcouncil.org (855) 452 2623

LUNGevity Foundation # A9
LUNGevity is the nation’s leading lung cancer organization providing support services and education for patients and caregivers, while investing in life-saving, translational research. LUNGevity’s comprehensive resources include a medically-vetted website, a 1-800 Help Line in partnership with CancerCare, a unique lung cancer navigator app, peer-to-peer matching for patients and caregivers (LUNGevity Life-Line), and survivorship conferences. LUNGevity also helps patients find and navigate clinical trials through our clinical trial finder tool, a Clinical Trial Ambassador program and participation with Emerging Med. LUNGevity’s vision is to create a world where no one dies from lung cancer.

Mesothelioma Applied Research Foundation # A16
The Mesothelioma Applied Research Foundation is the leading organization dedicated to eradicating mesothelioma and easing the suffering caused by it, by funding peer-reviewed mesothelioma research, providing patient support services and education, and advocating Congress for increased federal funding for research. Mesothelioma funding, per death, has historically been extremely low, especially when compared to other cancers. The Mesothelioma Applied Research Foundation was founded in 2000 to address this imbalance and since then has independently awarded over $9.4 million in mesothelioma research funding. More information is available at www.curemeso.org Please contact (877) 363-6376 or info@curemeso.org.
continued from previous page

MPN Research Foundation # A10
Founded by patients, the MPN Research Foundation is a catalyst for research funding in pursuit of new treatments – and eventually a cure – for myeloproliferative neoplasms (MPNs). To date, we have funded more than $11 million in MPN research. But research funding is only part of what we do. We’re also dedicated to helping you change your prognosis by serving as a valuable source of education and resources in the MPN community.

RN Cancer Guides Solutions # A11
RN Cancer Guides Solutions provides oncology nurse guidance to cancer patients and their families. We assist with the medical, financial and emotional barriers of their cancer diagnosis and treatment.

SHARE Cancer Support # A14
SHARE is a nationwide community offering support and information to women diagnosed with breast and ovarian cancers and their caregivers. All of our services are free of charge and provided by people who have faced these diseases and are trained to offer support. Our educational programs and webinars are presented by physicians, researchers, and practitioners specializing in breast and ovarian cancer care. We provide support helplines, support groups, educational programs, and advocacy activities. Call toll-free 844-ASK-SHARE to talk to a trained peer about breast, ovarian, or metastatic breast cancer.

The Leukemia & Lymphoma Society # A12
Founded in 1949, The Leukemia & Lymphoma Society (LLS) is the world’s largest voluntary health organization dedicated to funding blood cancer research, providing education and patient services and advocating for patient access to new therapies. Over the years, LLS has funded and continues to fund new treatments that are saving the lives of patients today. Contact our Information Specialists 800.955.4572, or go to www.LLS.org.

ThyCa: Thyroid Cancer Survivors’ Association, Inc. # A18
ThyCa: Thyroid Cancer Survivors’ Association, Inc., an international nonprofit organization advised by thyroid cancer specialists, educates and supports patients and families through its website, support groups, one-to-one support, free handbooks and packets, newsletters, free downloadable, low-iodine cookbook, webinars, workshops and conferences. 877-588-7904 (toll-free); PO Box 1102, Olney, MO 20830; thyca@thyca.org.

### NCCN Patient Advocacy Pavilion Sponsors

| Diamond | Eisai Inc. |
| Ruby | Celgene Corporation, Lilly Oncology, Pharmacyclics LLC, an AbbVie Company, Takeda Oncology |
| Emerald | AstraZeneca, Dendreon, Genentech, Genoptix, Gilead Sciences, Inc., Heron Therapeutics, Incyte Corporation |
| Topaz | AmerisourceBergen enterade® |

FREE App for Android and iOS

NCCN Patient Guides for Cancer

NCCN Guidelines for Patients®, translations of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), are meant to help patients with cancer talk with their physicians about the best treatment options for their disease.

NCCN Guidelines for Patients are available online at NCCN.org/patients or via the new mobile app.

NCCN invites you to download the FREE NCCN Patient Guides for Cancer App

NCCN Foundation gratefully acknowledges our supporters, AbbVie Inc., Amgen Inc., Astellas, Genentech, and Takeda Oncology for their support in making available this NCCN Guidelines for Patients® Mobile App. NCCN independently develops and distributes the NCCN Guidelines for Patients. Our supporters do not participate in the development of the NCCN Guidelines for Patients and are not responsible for the content or recommendations therein.
American Society of Clinical Oncology (ASCO) # 120
The American Society of Clinical Oncology (ASCO) is the world’s leading professional organization for physicians and oncology professionals caring for people with cancer. ASCO is the only organization that encompasses all oncology subspecialties, allowing our members to grow from the professional and personal expertise of their colleagues worldwide and across disciplines. Join ASCO at the meeting and receive immediate access to valuable member benefits. Current members stop by to receive your collectable ASCO pin!

AstraZeneca # 525
AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com

Bayer # 627
Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power.

BTG # 510
BTG Interventional Oncology is transforming the way cancer is treated with wide-ranging solutions of minimally-invasive, highly targeted therapies that can be personalized to each patient’s needs. Our products are used to treat or provide symptomatic relief for people with cancer and benign tumors. To learn more about BTG Interventional Oncology, please visit: btg-im.com.

Celgene Corporation # 602
Celgene Corporation (Nasdaq:CELG) is a global biopharmaceutical company that is helping healthcare providers turn incurable cancers into chronic, manageable diseases through innovative therapies. This dedication to medical progress goes hand-in-hand with our industry-leading patient support and access programs. Together, these aspects form the core of our commitment to patients worldwide. For more information, visit www.celgene.com.

Clovis Oncology # 339
We are a biopharmaceutical company focused on acquiring, developing and commercializing cancer treatments in the United States, Europe and other international markets. Our development programs are targeted at specific subsets of cancer, combining personalized medicine with companion diagnostics to direct therapeutics to those patients most likely to benefit from them.

Cumberland Pharmaceuticals # 625
Cumberland Pharmaceuticals is a specialty pharmaceutical company that acquires, develops and commercializes branded prescription products designed to improve quality of care and unmet medical needs. Ethyol® (amifostine) is an FDA-approved hospital product used in the prevention of xerostomia as a side-effect of radiation treatment for head and neck cancer. It is also indicated to reduce the cumulative renal toxicity associated with the repeated administration of cisplatin in patients with advanced ovarian cancer.

Eisai Inc. # 436
As the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., our passionate commitment to patient care is the driving force behind our efforts to help address unmet medical needs. We are a fully integrated pharmaceutical business with discovery, clinical, manufacturing and marketing capabilities. Our key areas of commercial focus include oncology and specialty care (Alzheimer’s disease, epilepsy and metabolic disorders). To learn more about Eisai Inc., please visit us at www.eisai.com/US.

Enterade® # 612
Enterade® is an innovative health sciences company dedicated to the development and commercialization of a portfolio of proprietary amino acid based products to address critical digestive, nutrition and hydration related health issues. The company’s flagship product, Enterade®, advanced formula, is a medical food for the dietary management of gastrointestinal dysfunction during cancer treatment.

Feel Good, Inc. # 618
Feel Good, Inc. provides portable TENS (transcutaneous electrical nerve stimulation) units offering a wide variety of benefits including alleviating back, nerve, post-op, diabetic pain, and migraines. Our units also improve circulation and sleep patterns to decrease the use of pain relievers that causes negative side effects.
### About Our Exhibitors

<table>
<thead>
<tr>
<th>#</th>
<th>Company</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>202</td>
<td>Genoptix Medical Laboratory</td>
<td>A leading CAP-accredited and CLIA-certified specialized laboratory focused on delivering diagnostic services to hematology/oncology patients and the physicians who treat them. The company includes over 200 trained professionals with PhDs, clinical laboratory scientists and pathologists – including over 30 board-certified hematopathologists, molecular pathologists and geneticists. Genoptix is an established center of excellence for oncology testing, specializing in five disease areas: breast, hematology, lung, melanoma, and colorectal cancer. Experience matters when interpreting oncology results.</td>
</tr>
<tr>
<td>203</td>
<td>Gilead Sciences</td>
<td>Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company’s mission is to advance the care of patients suffering from life-threatening diseases worldwide. Gilead has operations in more than 30 countries worldwide, with headquarters in Foster City, California.</td>
</tr>
<tr>
<td>206</td>
<td>Genentech USA, Inc.</td>
<td>A biotechnology company that discovers, develops and commercializes medicines to treat patients with serious or life-threatening medical conditions. We are among the world’s leading biotech companies, with multiple products on the market and a promising development pipeline.</td>
</tr>
<tr>
<td>207</td>
<td>Genomic Health, Inc.</td>
<td>Oncotype DX Recurrence Score: The Recurrence Score to determine Invasive Breast Cancer Prognosis and Prediction to Chemotherapy Benefit. Oncotype DX DCIS Score: Oncotype GPS for Prostate Cancer. Oncotype DX Colon: Genoptix, a Novartis Company, is a leading CAP-accredited and CLIA-certified specialized laboratory focused on delivering diagnostic services to hematology/oncology patients and the physicians who treat them. The company includes over 200 trained professionals with PhDs, clinical laboratory scientists and pathologists – including over 30 board-certified hematopathologists, molecular pathologists and geneticists. Genoptix is an established center of excellence for oncology testing, specializing in five disease areas: breast, hematology, lung, melanoma, and colorectal cancer. Experience matters when interpreting oncology results.</td>
</tr>
<tr>
<td>228</td>
<td>Jazz Pharmaceuticals, Inc.</td>
<td>Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is an international biopharmaceutical company focused on improving patients’ lives by identifying, developing and commercializing meaningful products that address unmet medical needs. The company has a diverse portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.</td>
</tr>
<tr>
<td>230</td>
<td>GE Healthcare</td>
<td>GE Healthcare offers a comprehensive portfolio for personalized breast care from screening to diagnosis. Products will include the Senographe Pristina - designed to reshape the mammography experience, Contrast Enhanced Spectral Mammography and Seno Iris mammography workstation.</td>
</tr>
<tr>
<td>233</td>
<td>INSYS Therapeutics</td>
<td>INSYS Therapeutics is a specialty pharmaceutical company that develops and commercializes innovative drugs and novel drug delivery systems for therapeutic molecules that improve the quality of patients’ lives. Using proprietary sublingual spray technology and our capabilities to develop pharmaceutical cannabinoids, we work to address the clinical shortcomings of existing pharmaceutical products.</td>
</tr>
<tr>
<td>236</td>
<td>Merck &amp; Co., Inc.</td>
<td>Merck (known as MSD outside the US and Canada) is a global health care leader working to help the world be well. Through our prescription medicines, vaccines, biologic therapies, and animal health products, we work to deliver innovative health solutions and are committed to increasing access to health care.</td>
</tr>
<tr>
<td>238</td>
<td>GenPath Oncology</td>
<td>GenPath, a CLIA and CAP certified national oncology / pathology laboratory, offers unmatched expertise and a comprehensive test menu. From routine clinical to advanced genomic testing for tumor sequencing and hereditary cancer syndromes, the full spectrum of the cancer patient work-up is covered. Our investment in new technologies and innovative partnership programs, such as our TC/PC NGS program, continuously sets our laboratory apart. GenPath is a division of BioReference Laboratories, an OPKO Health Company.</td>
</tr>
<tr>
<td>241</td>
<td>Janssen Biotech, Inc.</td>
<td>At Janssen Biotech, Inc., we have an urgent commitment to make a difference for cancer patients and those living with autoimmune diseases. Comprised of Janssen Oncology and Janssen Immunology, we deliver transformational biologic medicines to market, and have built a rich legacy of innovative firsts. For more information, visit <a href="http://www.janssen.com">www.janssen.com</a>.</td>
</tr>
<tr>
<td>247</td>
<td>Harborside Press</td>
<td>Harborside Press is the publisher of JNCCN-Journal of the National Comprehensive Cancer Network, which covers the entire spectrum of cancer care and includes updates on the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®); The ASCO Post, a newspaper featuring highly validated coverage of important issues in the field of quality cancer care; and Journal of the Advanced Practitioner in Oncology, a clinical journal for the nurse practitioner, clinical nurse specialist, and physician assistant.</td>
</tr>
<tr>
<td>253</td>
<td>Heron Therapeutics, Inc.</td>
<td>At Heron Therapeutics, our mission is to improve the lives of patients by developing best-in-class medicines that address unmet medical needs. We are developing novel, patient-focused solutions that apply our innovative science and technology to already-approved pharmacological agents. Our goal is to improve the safety and efficacy of products with well-known pharmacology and broaden their potential field of use. Our product portfolio includes an approved therapy for CIN and 2 additional products in development.</td>
</tr>
<tr>
<td>255</td>
<td>LeanTaS</td>
<td>What iQueue Operating Rooms mines OR case data and applies predictive analytics and machine learning to make block scheduling smart and efficient, and is designed to help drive fact-based planning and seamless execution: • Mobile Block Exchange makes it easy for surgeons to request/release blocks on their mobile device. • Smart Staffing uses machine learning to recommend staffing plans that minimize furloughs, call-backs and overtime. • Smart Performance Tracker helps surgeons and OR Managers make informed decisions and improve productivity. • Smart Block Scheduling uses machine learning to ensure the right surgeon gets the right block on the right day of the week.</td>
</tr>
<tr>
<td>259</td>
<td>Helsinn</td>
<td>Helsinn is a privately owned pharmaceutical group headquartered in Lugano, Switzerland, with operating subsidiaries in Ireland, the U.S., and a representative office in China. Helsinn is one of the world’s leading supportive care companies. Our portfolio of products combines therapies we license and those developed at Helsinn. <a href="http://www.helsinn.com">www.helsinn.com</a>.</td>
</tr>
<tr>
<td>260</td>
<td>Jazz Pharmaceuticals, Inc.</td>
<td>Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is an international biopharmaceutical company focused on improving patients’ lives by identifying, developing and commercializing meaningful products that address unmet medical needs. The company has a diverse portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.</td>
</tr>
<tr>
<td>261</td>
<td>Leadiant Biosciences, Inc.</td>
<td>Leadiant Biosciences, Inc. is a rare corporation dedicated to creating novel medicines for the unmet needs of patients with rare diseases. Truly unique in its field, Leadiant Biosciences, Inc. places its considerable scientific resources behind the discovery of compounds that benefit the few. Simply, because it’s the right thing to do. By maintaining an environment based on integrity, commitment, and placing the patient first, Leadiant Biosciences, Inc. is able to consider what may be a small commercial success nothing less than a human triumph.</td>
</tr>
<tr>
<td>262</td>
<td>GenPath Oncology</td>
<td>GenPath, a CLIA and CAP certified national oncology / pathology laboratory, offers unmatched expertise and a comprehensive test menu. From routine clinical to advanced genomic testing for tumor sequencing and hereditary cancer syndromes, the full spectrum of the cancer patient work-up is covered. Our investment in new technologies and innovative partnership programs, such as our TC/PC NGS program, continuously sets our laboratory apart. GenPath is a division of BioReference Laboratories, an OPKO Health Company.</td>
</tr>
<tr>
<td>263</td>
<td>Leadiant Biosciences, Inc.</td>
<td>Leadiant Biosciences, Inc. is a rare corporation dedicated to creating novel medicines for the unmet needs of patients with rare diseases. Truly unique in its field, Leadiant Biosciences, Inc. places its considerable scientific resources behind the discovery of compounds that benefit the few. Simply, because it’s the right thing to do. By maintaining an environment based on integrity, commitment, and placing the patient first, Leadiant Biosciences, Inc. is able to consider what may be a small commercial success nothing less than a human triumph.</td>
</tr>
<tr>
<td>264</td>
<td>Helsinn</td>
<td>Helsinn is a privately owned pharmaceutical group headquartered in Lugano, Switzerland, with operating subsidiaries in Ireland, the U.S., and a representative office in China. Helsinn is one of the world’s leading supportive care companies. Our portfolio of products combines therapies we license and those developed at Helsinn. <a href="http://www.helsinn.com">www.helsinn.com</a>.</td>
</tr>
<tr>
<td>266</td>
<td>Heron Therapeutics, Inc.</td>
<td>At Heron Therapeutics, our mission is to improve the lives of patients by developing best-in-class medicines that address unmet medical needs. We are developing novel, patient-focused solutions that apply our innovative science and technology to already-approved pharmacological agents. Our goal is to improve the safety and efficacy of products with well-known pharmacology and broaden their potential field of use. Our product portfolio includes an approved therapy for CIN and 2 additional products in development.</td>
</tr>
<tr>
<td>267</td>
<td>Helsinn</td>
<td>Helsinn is a privately owned pharmaceutical group headquartered in Lugano, Switzerland, with operating subsidiaries in Ireland, the U.S., and a representative office in China. Helsinn is one of the world’s leading supportive care companies. Our portfolio of products combines therapies we license and those developed at Helsinn. <a href="http://www.helsinn.com">www.helsinn.com</a>.</td>
</tr>
<tr>
<td>271</td>
<td>Harborside Press</td>
<td>Harborside Press is the publisher of JNCCN-Journal of the National Comprehensive Cancer Network, which covers the entire spectrum of cancer care and includes updates on the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®); The ASCO Post, a newspaper featuring highly validated coverage of important issues in the field of quality cancer care; and Journal of the Advanced Practitioner in Oncology, a clinical journal for the nurse practitioner, clinical nurse specialist, and physician assistant.</td>
</tr>
<tr>
<td>272</td>
<td>Heron Therapeutics, Inc.</td>
<td>At Heron Therapeutics, our mission is to improve the lives of patients by developing best-in-class medicines that address unmet medical needs. We are developing novel, patient-focused solutions that apply our innovative science and technology to already-approved pharmacological agents. Our goal is to improve the safety and efficacy of products with well-known pharmacology and broaden their potential field of use. Our product portfolio includes an approved therapy for CIN and 2 additional products in development.</td>
</tr>
<tr>
<td>273</td>
<td>Helsinn</td>
<td>Helsinn is a privately owned pharmaceutical group headquartered in Lugano, Switzerland, with operating subsidiaries in Ireland, the U.S., and a representative office in China. Helsinn is one of the world’s leading supportive care companies. Our portfolio of products combines therapies we license and those developed at Helsinn. <a href="http://www.helsinn.com">www.helsinn.com</a>.</td>
</tr>
<tr>
<td>274</td>
<td>GenPath Oncology</td>
<td>GenPath, a CLIA and CAP certified national oncology / pathology laboratory, offers unmatched expertise and a comprehensive test menu. From routine clinical to advanced genomic testing for tumor sequencing and hereditary cancer syndromes, the full spectrum of the cancer patient work-up is covered. Our investment in new technologies and innovative partnership programs, such as our TC/PC NGS program, continuously sets our laboratory apart. GenPath is a division of BioReference Laboratories, an OPKO Health Company.</td>
</tr>
<tr>
<td>275</td>
<td>Leadiant Biosciences, Inc.</td>
<td>Leadiant Biosciences, Inc. is a rare corporation dedicated to creating novel medicines for the unmet needs of patients with rare diseases. Truly unique in its field, Leadiant Biosciences, Inc. places its considerable scientific resources behind the discovery of compounds that benefit the few. Simply, because it’s the right thing to do. By maintaining an environment based on integrity, commitment, and placing the patient first, Leadiant Biosciences, Inc. is able to consider what may be a small commercial success nothing less than a human triumph.</td>
</tr>
<tr>
<td>276</td>
<td>Helsinn</td>
<td>Helsinn is a privately owned pharmaceutical group headquartered in Lugano, Switzerland, with operating subsidiaries in Ireland, the U.S., and a representative office in China. Helsinn is one of the world’s leading supportive care companies. Our portfolio of products combines therapies we license and those developed at Helsinn. <a href="http://www.helsinn.com">www.helsinn.com</a>.</td>
</tr>
<tr>
<td>277</td>
<td>GenPath Oncology</td>
<td>GenPath, a CLIA and CAP certified national oncology / pathology laboratory, offers unmatched expertise and a comprehensive test menu. From routine clinical to advanced genomic testing for tumor sequencing and hereditary cancer syndromes, the full spectrum of the cancer patient work-up is covered. Our investment in new technologies and innovative partnership programs, such as our TC/PC NGS program, continuously sets our laboratory apart. GenPath is a division of BioReference Laboratories, an OPKO Health Company.</td>
</tr>
</tbody>
</table>
About Our Exhibitors

Moffitt Cancer Center  # 418
Moffitt is dedicated to one lifesaving mission: to contribute to the prevention and cure of cancer. The Tampa-based facility is one of only 47 National Cancer Institute-designated Comprehensive Cancer Centers, a distinction that recognizes Moffitt’s excellence in research, clinical trials, prevention and cancer control. Moffitt is the No. 6 cancer hospital in the nation and has been listed in U.S. News & World Report. Moffitt’s expert nursing staff is recognized by the American Nurses Credentialing Center with Magnet® status. For more information, call 1-888-MOFFITT (1-888-663-3488), visit MOFFITT.org.

NeoGenomics  # 711
NeoGenomics is a premier cancer diagnostics and pharma services company serving oncologists, pathologists, pharmaceutical companies, academic centers, and others with innovative diagnostic, prognostic and predictive testing. Our vision embodies uncompromising quality, exceptional service, and innovative solutions. We have a network of CAP-accredited, CLIA-licensed facilities across the U.S., but work hard to maintain easy access and all the efficiencies of a smaller operation.

Novartis  # 232 & # 302
At Novartis, our mission is to discover new ways to improve and extend people’s lives. We use science-based innovation to address some of society’s most challenging health care issues. We discover and develop breakthrough treatments and find new ways to deliver them to as many people as possible. As a leader in oncology, Novartis offers a portfolio of more than 20 approved therapies and approximately 30 compounds in development.

Novocure, Inc.  # 432
Novocure (novocure.com) is a commercial-stage oncology company developing a novel, proprietary therapy called Tumor Treating Fields, or TTFields, for the treatment of solid tumour cancers. Headquartered in Jersey, Novocure has U.S. operations in Portsmouth, New Hampshire, Malvern, Pennsylvania, and New York City. Additionally, the company has offices in Germany, Switzerland and Japan, and a research center in Haifa, Israel.

ONCC provides nationally accredited certification programs for nurses in oncology and related specialties.

Personal Genome Diagnostics  # 117
PGDX’s comprehensive genomic technologies empower the fight against cancer. PGDX is driving toward broad patient access to its genomic approaches, through a CLIA-certified facility providing comprehensive genomic services, as well as its PROGENIES™ technology transfer solution and in vitro diagnostic products to enable other molecular laboratories to easily internalize testing.

Pfizer  # 520
Pfizer Oncology is committed to pursuing innovative treatments that are helping to redefine life with cancer. As an oncology leader with one of the most robust oncology pipelines in the industry, we are focused on translating scientific breakthroughs into clinical application. Additionally, we are dedicated to working collaboratively with the community to make a positive impact on people’s lives.

Sanofi Genzyme  # 528
Sanofi Genzyme, the specialty care business unit of Sanofi, focuses on rare diseases, multiple sclerosis, oncology, and immunology. We help people with debilitating and complex conditions that are often difficult to diagnose and treat. Our approach is shaped by our experience developing highly specialized treatments and forging close relationships with physician and patient communities. We are dedicated to discovering and advancing new therapies, providing hope to patients and their families around the world. Learn more at www.sanogeniczyme.com.

Seattle Genetics  # 531
Seattle Genetics is a biotechnology company focused on developing and commercializing innovative, empowered antibody-based therapies for the treatment of cancer. We are the industry leader in antibody-drug conjugates (ADCs), a technology designed to harness the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. ADCs are intended to spare non-targeted cells and thus reduce many of the toxic effects of traditional chemotherapy, while potentially enhancing antitumor activity. In addition to one marketed product, we are advancing a deep product pipeline to address significant unmet medical needs.

Sheridan Healthcare  # 412
Sheridan is a multispecialty physician group and healthcare management team providing anesthesia, emergency medicine, radiology, and women’s and children’s health services to more than 450 healthcare facilities in the nation. Sheridan’s collective experience from hundreds of local, customized engagements since 1953, culture of continuous lean process improvement, and team of experts in the business of healthcare enable Sheridan to better solve complex problems and consistently give healthcare organizations confidence in its execution.

Shire Translating Promising Science into Patient Benefits At Shire, we aim to make a difference in the lives of people living with cancer. The oncology market is one of the fastest growing and largest, but the need for new treatment options is clear. We are building an innovative, sustainable and diverse portfolio of new oncology therapies, and are accessing transformational science – and growing our global footprint – through strategic research and development partnerships.

Siemens Healthineers  # 512
Siemens Healthineers is committed to becoming the trusted partner of healthcare providers worldwide, enabling them to improve patient outcomes while reducing costs. Driven by our legacy of engineering excellence and our pharma business partners, we are a global leader in medical imaging, laboratory diagnostics, clinical IT, and services in the USA. Siemens.com/healthineers.

St. Peter’s Hospital  # 717
Why wait to vacation? Play where you LIVE! Nestled at the base of the Rocky Mountain Front, St. Peter’s Hospital is a progressive, state-of-the-art 123-bed independent community hospital in Montana’s capital city. Our community cancer center boasts:

• Commission on Cancer Accredited
• Patient Satisfaction 95th percentile
• Nursing staff are RNs and OCN certified
• Pharmacist and Social Worker in clinic
• 2 Nurse Navigators
• 22 chemo chairs
• 18 bed dedicated Oncology Unit with all RNs
• Radiation Oncology in Department
• PET/CT in Department

Sun Pharmaceutical Industries, Inc.  # 709
Enhance people’s lives with innovative and quality medicines, providing exceptional value to the communities in which we work. Please stop by our booth.

Taiho Oncology, Inc. Exhibit  # 530
Taiho Oncology has built a world class clinical organization that works to develop innovative cancer treatments. Taiho is focused on bringing novel technologies to cornerstone chemotherapies to a wide range of tumor types including colorectal cancer and a variety of solid tumors.
My name is Aimee. I am 42 years old, and this is my story...

In 2008, when I was only in my mid-30s, I began experiencing severe headaches. The pressure was debilitating and often accompanied by tinnitus and reddish, sunburn-like flushing on my face. I found it challenging to concentrate and began missing work. I knew something was wrong, so I became my own advocate.

I was referred to 9 different specialists, ranging from a neurologist to an endocrinologist. My hematology/oncology specialist completed a bone marrow aspiration. She also confirmed that I was JAK2 exon 12 mutation–positive. One month before my 40th birthday, with my hematocrit level dangerously high at 60.5%, I was finally diagnosed with polycythemia vera (PV). It took almost 6 years to receive my diagnosis. I only wish someone had recognized my symptoms as PV, and that I had been diagnosed sooner.

The MPN Landmark Survey* is a large-scale, extensive analysis to evaluate disease burden in patients with MPNs. The findings suggest that patients experience a broad symptom burden, which may negatively affect quality of life, activities of daily living, and work productivity.

Selected Survey Results in Patients With PV

- 66% reported that their symptoms diminished their quality of life
- 73% reported fatigue as a symptom
- 52% reported that pain/discomfort limited their daily activities
- 63% reported that PV interfered with family or social life

*The Myeloproliferative Neoplasm (MPN) Landmark Survey, funded by Incyte Corporation, was a web-based questionnaire composed of 65 multiple-choice questions intended to help evaluate the patient disease burden in the MPN disease setting. A total of 813 patients in the US with a previous diagnosis of myelofibrosis (MF), PV, or essential thrombocythemia (ET) completed the survey (MF, n = 207; PV, n = 380; ET, n = 226).

In 2008, when I was only in my mid-30s, I began experiencing severe headaches. The pressure was debilitating and often accompanied by tinnitus and reddish, sunburn-like flushing on my face. I found it challenging to concentrate and began missing work. I knew something was wrong, so I became my own advocate. I was referred to 9 different specialists, ranging from a neurologist to an endocrinologist. My hematology/oncology specialist completed a bone marrow aspiration. She also confirmed that I was JAK2 exon 12 mutation–positive. One month before my 40th birthday, with my hematocrit level dangerously high at 60.5%, I was finally diagnosed with polycythemia vera (PV). It took almost 6 years to receive my diagnosis. I only wish someone had recognized my symptoms as PV, and that I had been diagnosed sooner.

The MPN Landmark Survey* is a large-scale, extensive analysis to evaluate disease burden in patients with MPNs. The findings suggest that patients experience a broad symptom burden, which may negatively affect quality of life, activities of daily living, and work productivity.

Visit PVStateOfMind.com to access the MPN Landmark Survey findings.

## About Our Exhibitors

<table>
<thead>
<tr>
<th>Takeda Oncology # 205</th>
<th>TESARO # 532</th>
<th>Teva Oncology # 630</th>
</tr>
</thead>
<tbody>
<tr>
<td>Located in Osaka, Japan, Takeda is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to strive towards better health for people worldwide through leading innovation in medicine. Additional information about Takeda is available through its corporate website, <a href="http://www.takeda.com">www.takeda.com</a>.</td>
<td>TESARO is a biopharmaceutical company devoted to providing transformative therapies to people bravely facing cancer. We see new possibilities to responsibly develop and commercialize innovative treatments where others may not. Relationships are vital to the success of our business, and we are committed to being a trusted partner to the cancer community. For more information, please visit <a href="http://www.tesarobio.com">www.tesarobio.com</a>.</td>
<td>People are at the heart of what drives Teva Oncology. As a top oncology company in the US, we strive to improve the lives of people affected by cancer. Our focus is to provide solutions in hematologic malignancies, solid tumors and supportive care. At Teva Oncology, our vision is to change the course of cancer care one patient at a time.</td>
</tr>
</tbody>
</table>

---

There is no routine cancer. Just like no two people are exactly the same, neither are their cancers. Each patient’s cancer is fueled by different, unique elements that help cancer cells develop, survive, invade and grow. That’s why researchers and oncologists at The James study the unique genetic makeup of each patient’s cancer. As they discover what drives a patient’s cancer, they develop and deliver the most advanced targeted treatments, leading to better outcomes, faster responses, fewer side effects and more hope. To learn more, visit cancer.osu.edu/cancer.
There is no routine cancer.

Just like no two people are exactly the same, neither are their cancers. Each patient’s cancer is fueled by different, unique elements that help cancer cells develop, survive, invade and grow. That’s why researchers and oncologists at The James study the unique genetic makeup of each patient’s cancer. As they discover what drives a patient’s cancer, they develop and deliver the most advanced targeted treatments, leading to better outcomes, faster responses, fewer side effects and more hope. To learn more, visit cancer.osu.edu/cancer.
Caring for cancer differently...

It’s all in the delivery

Taiho Oncology, Inc., is focused on bringing novel technology to cornerstone chemotherapies for a wide range of tumor types, including a variety of solid tumors. By developing oral oncolytic therapies, we are aspiring to deliver more meaningful moments to patients and to redefine the way the world treats cancer.

To learn more, please visit www.TaihoOncology.com.
What was surprising to me about colon cancer is that it is preventable and treatable, yet it is the second most lethal form of cancer in the United States. That can’t be.

Luke Perry
Friend of Sheila Schrack

Sheila Schrack
Stage IIIc survivor

FROM DIAGNOSIS TO SURVIVORSHIP, WE’RE BEHIND YOU & YOUR PATIENTS 100%.

We’re here to help you fight! We create guides, magazines, podcasts, webinars and more to help you and your patients learn about colorectal cancer and the best ways to fight it.

GET FREE PATIENT RESOURCES: FightCRC.org/Resources

See why Luke Perry has joined the fight against colorectal cancer

FightCRC
At Cancer Hope Network, we know those can be three of life’s most terrifying words. But like you, we know they are the beginning of a sentence, not the end.

For more than 30 years, we have provided free one-on-one support for adult cancer patients and their loved ones. Our 400+ trained Support Volunteers are at least one year post-treatment or successfully undergoing maintenance therapies. They offer support from diagnosis, through treatment and into survivorship.

For more information or to learn how we can support your patients, come see us in the Exhibit Hall, visit cancerhopenetwork.org or call 877-HOPENET.
“Whether it was where to get help, ideas for financial support, or information about colon cancer – I’ve found it with the Colon Cancer Alliance. I’m extremely grateful to have you all!”

Michele M.

We empower patients with the information, resources and support they need to make decisions with confidence after a colorectal cancer diagnosis.

When you have kidney cancer, remember just one thing:

KidneyCancer.org
We’re MPN RESEARCH FOUNDATION, a patient-centered non-profit that works to change the prognosis of those living with rare blood cancers.

LBBC’s free publications provide your patients with easy-to-understand breast cancer information and resources.

Connecting you to trusted breast cancer information and a community of support.

Visit lbbc.org/guides
we can see the end of cancer from here.

The mission of The Leukemia & Lymphoma Society (LLS) is: Cure leukemia, lymphoma, Hodgkin’s disease and myeloma, and improve the quality of life of patients and their families. LLS exists to find cures and ensure access to treatments for blood cancer patients. We are the voice for all blood cancer patients and we work to ensure access to treatments for all blood cancer patients.

Professional Education
To view free professional education videos and additional professional resources, visit www.LLS.org/professionaled.

Patient Education
To view free patient education videos, visit www.LLS.org/educationvideos. To view free education telephone/web programs, visit www.LLS.org/programs.

Learn more about the information LLS provides by visiting www.LLS.org or call an LLS Information Specialist at (800) 955-4572, Monday to Friday, 9 a.m. to 9 p.m. ET.

SHARE is a nationwide community that offers free support and information to women diagnosed with breast and ovarian cancers and their caregivers.

LatinaSHARE
Survivor-Patient Navigators
Caregiver Support
Advocacy
Helpline in 15 Languages
Online Communities

Support Groups
Educational Programs
Webinars
Pink & Teal Corporate Wellness Program
Outreach to underserved communities

Helpline: 844-ASK-SHARE

www.sharecancersupport.org
www.latina.sharecancersupport.org

@SHAREing
@SHARECancerSupport
<table>
<thead>
<tr>
<th>Poster #</th>
<th>Primary Author and Institution</th>
<th>Title</th>
<th>Co-Authors</th>
<th>Category</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Amy Connolly, BSc</td>
<td>Towards Personalised Medicine: Is the Quantity of High Grade Dysplasia on Cervical Biopsy Predictive of Subsequent Loop Electrosurgical Excision Procedure of the Transformation Zone?</td>
<td>Paul Hartl, MD; Clive Klippen, MBBSch</td>
<td>Best Practices in Implementation and Use of Clinical Practice Guidelines</td>
</tr>
<tr>
<td>2</td>
<td>Mohamed A. Zazouz, MD, MSc</td>
<td>Optimizing Cancer Surveillance Protocols for Low-Risk Pediatric Brain Tumors Using Tumor Behavior Patterns</td>
<td>Peter E. Manley, MD; Mohammed AllMehdir; MSC; Nicole J. Ulrich, MD; PhD; Hormuzdar H. Dasavarch, MD; MPH; Liliana C. Guzmenna, MD, FRSCC</td>
<td>Best Practices in Implementation and Use of Clinical Practice Guidelines</td>
</tr>
<tr>
<td>3</td>
<td>Rahab Abdul El Wahab, BSc, MSc; Pharm, RPh</td>
<td>Assessment of Deep Vein Thrombosis (DVT) Cases in Ambulatory Cancer Patients in Qatar: A Retrospective Case Control Study</td>
<td>Shereen Elazazpi, RPh; BSc Pharm, Pharmd, CAPC; Raham Hassan Hegom Eldin, MD; BCh; CPPhG; SSGB; Noval Abdulahm Al Tarzaneh, ICP; COAP, COQA, CTBCT, Fellow HH; Fellow RPh, Fellow ISGUA</td>
<td>Best Practices in Implementation and Use of Clinical Practice Guidelines</td>
</tr>
<tr>
<td>4</td>
<td>Julia Tromman, PhD, MBA</td>
<td>Facilitating Delivery of Guideline-Recommended Cancer Care with a Written Care Plan: Pre-Implementation Data From the 4th in Oncology Project</td>
<td>Christina S. Weldon, MBA; Claudia B. Peretz, DO; Swati A. Kulkarni, MD; Seema A. Khan, MD; MPH; Nora M. Hansen, MD; Valerie M. Nelson, MD, MBA; Jennifer Stien, RN, MPH; MA; Melissa A. Simon, MD, MPH; Jonathan B. Strauss, MD, MBA; Sasa M. Epiquin, MD; Mikiko M. Buncy, MD, MPH; Wayne Pan, MD, PhD; Sarah M. Friedewald, MD; William J. Gradishar, MD</td>
<td>Best Practices in Implementation and Use of Clinical Practice Guidelines</td>
</tr>
<tr>
<td>5</td>
<td>Karen Herold, DNP, FNP-BC; WHCNP-BC</td>
<td>Improving the Quality, Effectiveness and Efficiency of Breast Cancer Care Using the NCCN Guidelines: A Report from a Community Hospital</td>
<td>Allyson Brooks, MD; Ahtam Jadaa, PhD, RN</td>
<td>Best Practices in Implementation and Use of Clinical Practice Guidelines</td>
</tr>
<tr>
<td>6</td>
<td>Chang-l Hsu</td>
<td>The Efficacy of Immunotherapy as First-Line Treatment in Advanced Non-Small Cell Lung Cancer: A Network Meta-Analysis</td>
<td>Yung-Tzu Chang, MS; Je-Lian Yang; Chin-Chuan Hung</td>
<td>Best Practices in Implementation and Use of Clinical Practice Guidelines</td>
</tr>
<tr>
<td>7</td>
<td>Janell Snapp, MSN, RN, FFCCN</td>
<td>Implementation of NCCN Adult Cancer Pain Management Guidelines into Oncology Clinics</td>
<td>Sachin Kale, MD; Erin Husser MB,RT(R)(T) LSSBBB</td>
<td>Best Practices in Implementation and Use of Clinical Practice Guidelines</td>
</tr>
<tr>
<td>8</td>
<td>Pere Gascon, MD, PhD</td>
<td>European Edition (Spain) of the NCCN Clinical Practice Guidelines: Relevance of the Translation and Adaptation Into Spanish</td>
<td>Carlos Camps, MD, PhD; Eduardo Diaz-Rubio, MD, PhD; Alfredo Carrato, MD; PhD; Rafael Lopez, MD, PhD; Margarita Faygon, MD; Vicente Guillem, MD, PhD</td>
<td>Best Practices in Implementation and Use of Clinical Practice Guidelines</td>
</tr>
<tr>
<td>10</td>
<td>Margaret Rausa, PharmD</td>
<td>Frequency of Guideline “Preferred” Chemotherapy Selection for the Treatment of HER2 Negative Breast Cancer</td>
<td>Richard Weininger, MD; Les Newcomer, MD; Nick Andrews, PharmD; Kurt Andrews, PhD; Eric Grattis, MD</td>
<td>Best Practices in Implementation and Use of Clinical Practice Guidelines</td>
</tr>
<tr>
<td>11</td>
<td>Mark S. Chambers, DMD, MS</td>
<td>Investigation of Gelclair® Bioadherent Oral Gel: Novel Analyses and a Proposed Study on Oral Mucositis Development and Management in Comparison to Magic Mouthwash/SOD</td>
<td>Katherine Ciarrocucio, DMD, MSeal; Mary Kay Delmedico, PhD; Andrea True Kelly, PhD</td>
<td>Best Practices in Implementation and Use of Clinical Practice Guidelines</td>
</tr>
<tr>
<td>12</td>
<td>Christine Bruzone Weldon, MBA</td>
<td>Pilot Results of Consolidated Screening Tool for Distress and Supportive Oncology Needs</td>
<td>Nancy Vence, BA; Amy Scheu, MSH; Lauren Allison Wiebe, MD; Shelly S. Lo, MD; Catharine Duvant, MD; Betty Roggeman, BA; Uzef Patel, MD; Paramvej Khosa, MD; Patricia A. Rohlman, MD; Ana Gordon, AM, LSH; Frank Penedo, PhD; James Garhart, PhD; Teresa Lills, PhD; William Dale, MD, PhD; Eileen Knightly, MBA, BSN, RN; Rosa Berardi, BA; Julia R. Tromman, PhD, MBA</td>
<td>Best Practices in Implementation and Use of Clinical Practice Guidelines</td>
</tr>
<tr>
<td>13</td>
<td>Julienne Hibs, DO, MBA</td>
<td>Compliance with Granulocyte Colony-Stimulating Factor (G-CSF) Use Guidelines and Its Impact on Length of Hospital Stay for Febrile Neutropenia</td>
<td>Amanda Blackmon, DD; David Henny, MD; Amy Joshi, DO, MBA</td>
<td>Best Practices in Implementation and Use of Clinical Practice Guidelines</td>
</tr>
<tr>
<td>14</td>
<td>George Daniel Grise, MD, PhD</td>
<td>Optimizing Post-Treatment Surveillance in Locally Advanced Non-Small Cell Lung Cancer Patients Following Definitive Chemoradiotherapy</td>
<td>Arash O. Naghavi, MD, MS; Yazen A. Absudeh, MD; Bradford A. Perez, MD; Thomas J. Dilling, MD, MS</td>
<td>Best Practices in Implementation and Use of Clinical Practice Guidelines</td>
</tr>
<tr>
<td>15</td>
<td>Bushra Ajaz, MD</td>
<td>Compliance with Testing for ESFR and ALK Mutations in Metastatic Non-Small Cell Lung Cancer: An Institutional Retrospective Analysis</td>
<td>Nia Manley, MD; Jennifer Tseng, MD; Timm Johnson, MD</td>
<td>Best Practices in Implementation and Use of Clinical Practice Guidelines</td>
</tr>
<tr>
<td>16</td>
<td>Brett Fleisher, BS</td>
<td>Connectivity Map of Current Biomarkers for the Advancement of Targeted Therapy in Triple-Negative Breast Cancer</td>
<td>Sitem Ali-Oudhia, PharmD, PhD</td>
<td>Bioinformatics/Information Technology Sciences</td>
</tr>
<tr>
<td>17</td>
<td>Huaping Yuan</td>
<td>Dual-energy Computed Tomography: Clinical Applications in Invasive Pulmonary Aspergillosis</td>
<td>N/A</td>
<td>Clinical Oncology</td>
</tr>
<tr>
<td>18</td>
<td>Huaping Yuan</td>
<td>Analyse the Association of Dynamic Changes in Chest Computed Tomographic (CT) Imaging with Clinical Symptoms and Signs Under Hematological Neutropenic Patients with Invasive Pulmonary Aspergillosis (IPA)</td>
<td>N/A</td>
<td>Clinical Oncology</td>
</tr>
<tr>
<td>19</td>
<td>Kamal Akbarov, PhD</td>
<td>Efficacy of MRI Based Cervical Cancer Brachytherapy Planning</td>
<td>Ias Iasay, Professor; Etchun Galipov, PhD; Nigar Alyyeva, Dr</td>
<td>Clinical Oncology</td>
</tr>
<tr>
<td>20</td>
<td>Kim Funah, MD</td>
<td>Percutaneous MRI-Guided Breast Biopsies: Tissue Marker Migration Rates and Associated Factors</td>
<td>Andrew Prether, MD; R. Jared Weinfurtner, MD</td>
<td>Clinical Oncology</td>
</tr>
<tr>
<td>Poster #</td>
<td>Primary Author and Institution</td>
<td>Title</td>
<td>Co-Authors</td>
<td>Category</td>
</tr>
<tr>
<td>----------</td>
<td>-------------------------------</td>
<td>-----------------</td>
<td>------------</td>
<td>----------</td>
</tr>
<tr>
<td>21</td>
<td>Dongmei Gao, MD</td>
<td>Downregulation of Cancer Stroma and Epithelial Cxcl1-I Predicts Poor Progression of Non-metastatic Tripa Negruent Breast Cancer: Involvement of Cxcl1-I in Tumor Proliferation and Invasion</td>
<td>Tianran Zhu, MD, PhD; Frank Ma, MS; Xiaodong Feng, PhD, PharmD</td>
<td>Clinical Oncology</td>
</tr>
<tr>
<td>22</td>
<td>Li Gao, MD</td>
<td>Clinical Value of the Combining Detection of Galectin-10 Test and Computed Tomographic Findings for Diagnosis of Invasive Pulmonary Aspergillosis</td>
<td>N/A</td>
<td>Clinical Oncology</td>
</tr>
<tr>
<td>23</td>
<td>Jie- Yi Shi, PhD</td>
<td>The Candidate Tumor Suppressor FOXO8 Inhibits Tumor Aggressiveness and Associates with Favorable Clinical Outcome in Human Hepatocellular Carcinoma</td>
<td>Jian Zhou; Jia Fan; Qiang Gao, MD</td>
<td>Clinical Oncology</td>
</tr>
<tr>
<td>24</td>
<td>Luay Mousa, MD</td>
<td>The Impact of Granulocyte Colony Stimulating Factor Use on Outcome of Patients with Metastatic Breast Cancer Treated with Chemotherapy</td>
<td>Michael Berger, PharmD; Julie Stephens, MD; Bhuvanewari Ramasawamy, MD; Maryam Lunberg, MD; Nicola Williams, MD; Raquel Randolfi, MD; Robert Wesolowski, MD</td>
<td>Clinical Oncology</td>
</tr>
<tr>
<td>25</td>
<td>Kassem Faraj, BS</td>
<td>A Comparison of Office Based Ultrasound Guided Renal Mass Biopsies Performed by Urologists and Standard Hospital Biopsies for Small Renal Masses</td>
<td>Chirag N. Dave, MD; Kunal Patel, MD; Brian Sellman, MD; Stephen Varian, MD; Rene Frontera, MD; Ryan Nelson, DO; Edward W. Schervish, MD</td>
<td>Clinical Oncology</td>
</tr>
<tr>
<td>26</td>
<td>Mira Qaiser Baig, MD</td>
<td>Impact Of Choromoradiotherapy in Advance Oral Cancers with Overall Survival, Loco-regional Control and Toxicity Profile in Comparison to Conventional Radiotherapy</td>
<td>N/A</td>
<td>Clinical Oncology</td>
</tr>
<tr>
<td>27</td>
<td>Karen Hick, PF, MS, CLT-LANA</td>
<td>Home Intervention for Chemotherapy Induced Peripheral Neuropathy: Sensormotor Program</td>
<td>Amy Darragh, PhD, OTR/L, FAOTA; Lekin Gaerke, OTR/L, CHT; Karl Vicary</td>
<td>Clinical Oncology</td>
</tr>
<tr>
<td>28</td>
<td>James J. Harding, MD</td>
<td>Interin Analysis of a Phase 1 Study of Esacutamidine in Patients with Advanced Hepatocellular Carcinoma</td>
<td>Robin K. Kelley, MD; Benjamin Tan, MD; Khyroyna Uhltalykh, BA; Carly Purcell, BA; Kem E. Muncel, BA; Richard Do, MD; Marisela Capano, PhD; Carmen Ruiz, MS; Mariam Rodriguez Lee, PhD; John Wilton, PhD; Peter Kuhn, PhD; Jenu Shi, MD; Renuka Iyer, MD; Ghassan K. Abou-Alkh</td>
<td>Clinical Oncology</td>
</tr>
<tr>
<td>29</td>
<td>Douglas B. Johnson, MD</td>
<td>Long-Term and Cardiometabolic Effects of anti-PD-1/PD-L1 Agents Used in the Treatment of Advanced Thyroid Cancer</td>
<td>Jialin J. Mosial, MD; Katy E. Beckermann, MD, PhD; Emily H. Castellana, MD; Megan H. Pollak, PharmD; Leora Horn, MD; David Chiem, MD; Igor Punzov, MD; Christine M. Lody, MD; PhD; Debra L. Friedman, MD; Jeffrey A. Sosman, MD</td>
<td>Clinical Oncology</td>
</tr>
<tr>
<td>30</td>
<td>Thephit Sediene, MD, PhD</td>
<td>Medical University Sofia Prognostic Model for Predicting the Risk of Local Recurrence After BCS for DCIS</td>
<td>Mariela Vasileva, MD, PhD; Todor Kandurahdri, PhD; Tatiana Hadijeva, MD, PhD</td>
<td>Clinical Oncology</td>
</tr>
<tr>
<td>31</td>
<td>Gianluca Rizzo, MD</td>
<td>Transanal Endoscopic Microsurgery After Necroablative Radiochemotherapy for Locally Advanced Extraperitoneal Rectal Cancer</td>
<td>Giuseppe Zaccarini, MD; Michele Magnacavallo, MD; Claudio Mattana, MD; Donato Paolo Pafundi, MD; Maria Antonietta Gambacorta, MD; Vincenzo Valentini, Professor; Claudio Coccio, Professor</td>
<td>Clinical Oncology</td>
</tr>
<tr>
<td>32</td>
<td>Mankandan Lakshmanan, MS</td>
<td>Malignant Ulcer: An Institutional Experience from Northern India</td>
<td>Vijay Kumar, MS, MCh; Arun Chaturvedi, MS, MAMS; Sanjeev Misra, MS, MCh; Sameer Gupta, MS, MCh; Naseem Akhtar, MS, MCh, MSc; Sudip Gang, MS; Kanitha Jain, MS</td>
<td>Clinical Oncology</td>
</tr>
<tr>
<td>33</td>
<td>Mankandan Lakshmanan, MS</td>
<td>Germ Cell Tumor Ovary: An Institutional Experience of Treatment &amp; Long Term Outcome</td>
<td>Sameer Gupta, MS, MCh; Arun Chaturas, MS, MAMS; Sanjeev Misra, MS, MCh; Vijay Kumar, MS, MCh; Naseem Akhtar, MS, MCh, MSc; Kanitha Jain, MS; Sudip Gang, MS</td>
<td>Clinical Oncology</td>
</tr>
<tr>
<td>34</td>
<td>Lalima Shah, MBBS, FCPS</td>
<td>Frequency of CA Breast in Difference Age Groups Presenting with Breast Mass</td>
<td>N/A</td>
<td>Clinical Oncology</td>
</tr>
<tr>
<td>35</td>
<td>Cenamor Thommashan Kamikul, MD</td>
<td>Prospective Evaluation of Acute Toxicity and Pathological Response of Patients Treated with Platinum Based Induction Chemotherapy in Locally Advanced Ovarian Cancer</td>
<td>Jibin Jose, MBBS; Rajnish Rai Kumar, MD; Malu Raffi, DNB; Tejas Bhathacharyya, MD; Milan A., MD; Ramadas Kunnabath, MD</td>
<td>Clinical Oncology</td>
</tr>
<tr>
<td>36</td>
<td>Matsuja Gopchhati, MD, PhD</td>
<td>Predictive Markers of Response in a Phase II Trial of Alectinib in Advanced Metastatic Lung Cancer</td>
<td>Austin Miller, PhD; Kishen E. Salerno, MD; Dan Iancu, MD; Karen Yone, NP; Jill Nettics, MS, ANP-C; Dominic Lamonica, MD; Arabia A. Adjei, PhD; Nikhil I. Khushalani, MD</td>
<td>Clinical Oncology</td>
</tr>
<tr>
<td>37</td>
<td>Abhinandan Mahapatra, MCh</td>
<td>The Clinical Significance of the Ratio TRB727 for Non-Muscle Invasive Bladder Cancer in Indian Scenario</td>
<td>Arup Kumar Mandal, MCh; Ravinshan S. Savaduru, MCh; Shrawan Kumar Singh, MCh; Sananta Modak, MCh; Nandita Kakkar, MS, MCh; Khushalani, MD</td>
<td>Clinical Oncology</td>
</tr>
<tr>
<td>38</td>
<td>Alam Arz Shari, MD</td>
<td>HER2 Receptor Expression in Breast Cancer Patients - Single Institutional Study from Saudi Arabia</td>
<td>Fatema Ibrahim Alshahwah, MCh; Bandar Aljebari, MCh; Yousuf AlKabesh, MCh</td>
<td>Clinical Oncology</td>
</tr>
<tr>
<td>39</td>
<td>Sam Chang, MD</td>
<td>Low Incidence of Microscopically Prostate Cancer Patients Treated with Polymer Delivered, Subcutaneously Administered Leuprolide Acetate</td>
<td>Stuart Atkinson, MB ChB; John A. McLane, PhD; Christopher Piezczonka, MD</td>
<td>Clinical Oncology</td>
</tr>
<tr>
<td>40</td>
<td>Yasser Anwar Abdelsabah, MCh</td>
<td>The Role of Chemoablation Therapy in Initially Metastatic Anal Canal Cancer Patients: A National Cancer Data Base Review</td>
<td>Christel Rushing; Manisha Paltu, MD; Christopher Willet, MD; Berceda Peterson, PhD; Brian Calto, MD</td>
<td>Clinical Oncology</td>
</tr>
</tbody>
</table>
Hosted by NCCN Oncology Research Program (ORP)

Poster # Primary Author and Institution Title Co-Authors Category

41 Ali Raufi, MD, FACP ECCO/Marshall University Clinical Outcome of Octogenarian Cancer Patients: A Comprehensive Cancer Center Experience Haasen Jafri, MD; Todd Gress, MPH Clinical Oncology

42 Julia Chatil, MD Candidate Ohio State University College of Medicine Breast Cancer Among Young Adults: A Retrospective Analysis of Racial Differences Anupama Suresh; Manily Palettas, MPH; Raquel E.E. Reisbott, MD; Bhuvana Ramasamy, MD; Robert Wesołowski, MD; Anne Noonan, MD; Sagar Sardesai, MD; Shadana Dewari, MD; Maryam Luntberg, MD Clinical Oncology

43 Abdul Rehman Naqvi, MD Lai W. Jenkins Cancer Center Clinical and Prognostic Characteristics of Testicular Teratomas with Rhabdomyosarcomatous Differentiation: A Meta-Analysis Paul Walker, MD, FACP Clinical Oncology

44 E. Gabriela Chiorean, MD Meditechmedia.com Performance Status Dynamics During Treatment with nab-Paclitaxel Plus Gemcitabine Vs. Gemcitabine Alone for Metastatic Pancreatic Cancer Daniel D. Von Hoff, MD, FACP; Yn Wan, MS, BS;Pharm; Sandra Margonato-Debey, PharmD, MBA; Marc Bottonian, MSc; David Goliathos, MBBS, FRACP Clinical Oncology

45 Olga Brokina, PhD Government Scientific Center of Federal Medical and Biological Agency of Russia Genes of Reparation System: Targeted NGS as a Tool to Investigate Population Difference of Hereditary Ovarian and Breast Cancer Marat Gondor; Leila Shigapova; Raisa Kuzef; Dmitry Khudry; PhD; Oleg Glav; PhD; Elena Shagimardanova, PhD; Kedrosa Anna, MD; Professor; Ksaya Valentin; Alexey Nikitin, MD Correlative/Genomic

46 Todd M. Morgan, MD University of Michigan Comprehensive Cancer Center Prognostic Utility of a Multi-gene Signature (The Cell Cycle Proliferation Score) in Patients with Renal Cell Carcinoma (RCC) After Radical Nephrectomy Riftel Mehta, MD; Paolo Tienese, PhD; J. Stuart Wolf, MD; Steven Stone, PhD; Chin-Lee Wu, MD; Adam S. Feldman, MD Correlative/Genomic

47 James Stewart Blachly, MD The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute Quantification of FLT3 Internal Tandem Duplication (FLT3-ITD) Status by Amplicon High Throughput Sequencing Produces Superior Estimates of Patient Survival Versus Capillary Electrophoresis An-Kathleen Elshid, MD; Jessica Kolsteckom, PhD; Drena Nicola, PhD; Shelley Orinck, BS; Jonathan L. Kolitz; MD; Bayard L. Powell, MD; Eunique Wang, MD; Richard M. Stone, MD; David Lucus, PhD; Jing Wen, MB; Krzysztof Mrezn, MD; Clara D. Bloomfield, MD; John C. Byrd, MD Correlative/Genomic

50 Laura E. Heppe, PharmD, MPH Humana Inc Incidence of Non-Melanoma Skin cancer in the Medicare Advantage Population Howard Rogers, MD; Jonas Puentz; Bryan Loy, MD; Marn Beveridge, MD Epidemiology/Risks

51 Muhammad Saad Hanmi, MD Wayne State University Second Primary Malignancy After Liver Transplantation in Hepatocellular Carcinoma: A SEER Analysis Rahi Shameem, MD; Filip Pancari, MD Epidemiology/Risks

53 Sandra Hatch, MD, FAACS, FACCS, FACR University of Texas Medical Branch at Galveston Development of an Algorithm to Identify Women with Ductal Carcinoma In Situ from Medicare Data Jacqueline M. Birn, MPH; MPH; Yu-Li M Lin, MS; Sharon H. Giordano, MD; MHP; H; Colleen Silva, MD, FAC; Fang-Yong Kun, PhD Outcomes and Health Services Research

54 Myrin Aung Win, MD The University of Texas MD Anderson Cancer Center Side Effects of Immune Checkpoint Therapy in Cancer Patients Visiting the Emergency Department of a Comprehensive Cancer Center Kyae Zin Thein, MD; Alhama Qassasat, MD; Mynt Min Han, MD; Sai-Ching Lim Young, MD, PhD Outcomes and Health Services Research

55 Teo G, PhD HealthCore Phototherapy Utilization Patterns and Costs Among Patients with Mycosis Fungoides Cutaneous T-cell Lymphoma: A Retrospective Database Study in a Commercially Insured US Population Yuan Tsang, MD, PharmD; Gaurav Sharma, PharmD; Marian Sapessi, PharmD; Hangkyu Tan, MS, PharmD; William Drake III, PharmD Outcomes and Health Services Research

56 Amelia Preij, MD Umberto I Pediatrico di Roma Radiation 223 Ditide: In Patients with mCRPC: Safety, Pain Relief and Efficacy in Real Life - A Retrospective Analysis of a Single Center Experience Sara Elena Rebuzzi, MD; Chiara Pozzi, MD; Viviana Frontelazz, MD; Gius Anna Follacci, MD; Angela Giuli, MD; Silverio Toma, MD; Giuseppe De Vincentis, MD; Vincenzo Bianco, MD Outcomes and Health Services Research

57 Daniel Lenzhan, MD Vanderbilt-Ingram Cancer Center Evaluation of Cardiovascular Disease Among Patients with Multiple Myeloma Receiving Different Drug Classes of Antimyeloma Treatment in the United States Ravi Pittal; Harinath Kamakande; Acanatriror Dacopp, MD; Clara Chen, MD, MS Outcomes and Health Services Research

58 Dominic Pilon, MA Groupe d’analyse, Lifes Prostate-Specific Antigen (PSA) Progression in Patients Treated with Alitretinoin Aceta Plus Prednisone (AP) or Placebo Plus Prednisone and Correlation with Overall Survival (OS): An Exploratory Post-Hoc Analysis of COU-AA-032 Trial Data Ajay S. Bell, PhD; Rhamon Karmat, MSc; Yolking Xiao, MD; Marie-Hélène Lafeuille, MA; Patrick LeFevre, MA; Stephen J. Freedland, MD Outcomes and Health Services Research

59 Nanum Li, PhD Analysis Group Inc Treatment Disruption of First-Line Endocriine and Chemotherapy Among Post-Menopausal Women with HR+/HER2- Metastatic Breast Cancer (mBC) Ella X. Du, MSc; Miranda Pespeles, BA; Lihao Chiu, PhD; Jipan Xin, MD, PhD; Victoria Barghout, MSPh; Derek H. Tang, PhD Outcomes and Health Services Research

60 Ancilla W. Fernandes, PhD AstraZeneca Pharmaceuticals LP Progression-Free Survival in Advanced Head and Neck Cancer: Retrospective Analysis of a Community Oncology Database Maxine D. Fisher, PhD; Temtopen O. Osufade, PhD; Paul J. Miller, MD; Mark S. Walker, PhD; Moon Fenton, MD Outcomes and Health Services Research
<table>
<thead>
<tr>
<th>Poster #</th>
<th>Primary Author and Institution</th>
<th>Title</th>
<th>Co-Authors</th>
<th>Category</th>
</tr>
</thead>
<tbody>
<tr>
<td>61</td>
<td>Shivani Pandya, MS</td>
<td>Real-World Healthcare Costs Among Nealy-Diagnosed Multiple Myeloma Patients in the United States Veteran Population (FY 2011-2015)</td>
<td>Safiya Alouzaid, PharmD, MPH; Lin Xie, MA, MS; Kael Parikh, BPharm, MS; Onur Basar, MS, PhD; Manali I. Patel, MD, MPH, MS</td>
<td>Outcomes and Health Services Research</td>
</tr>
<tr>
<td>62</td>
<td>Chi-Chang Chen, PhD, Ms Pharm</td>
<td>Real-World Adherence, Treatment Patterns and Outcomes in Patients with Multiple Myeloma Initially Treated with Lenalidomide + Bortezomib + Dexamethasone</td>
<td>Kael Parikh, BPharm, MS; Safiya Alouzaid, PharmD, MPH; Catherine B. McGuiness, MA; Ali McBride, Pharm D, MS; BCP; Faisa Zafar, MPAS; Robin Wade, Rph, MS</td>
<td>Outcomes and Health Services Research</td>
</tr>
<tr>
<td>63</td>
<td>Frank Xiangning Liu, PhD</td>
<td>Patient and Oncologist Preferences for Attributes of Drug Therapy in Advanced Melanoma: A Discrete Choice Experiment</td>
<td>Edward A. Wilf, PhD; Enid W. Ebbinghaus, MD; Grace DiBiondavento Beyer, MBA; Enriqe Basurto, MSc; Richard W. Joseph, MD</td>
<td>Outcomes and Health Services Research</td>
</tr>
<tr>
<td>64</td>
<td>Christine M. Veenstra, MD, MSHP</td>
<td>Partnered Status &amp; Receipt of NCCN Guideline-Concordant Colon Cancer Care</td>
<td>Sarah T. Hawley, PhD, MPH; Mousseni Barnerjee, PhD; Jennifer J. Griggs, MD, MPH</td>
<td>Outcomes and Health Services Research</td>
</tr>
<tr>
<td>65</td>
<td>Min Huang, PhD</td>
<td>Cost-Effectiveness of Pembrolizumab vs. Standard-of-Care Chemotherapy in 1st Line Treatment of PD-L1 Positive Metastatic NSCLC Patients</td>
<td>Yangyan Lou, MD; James Pellissier, PhD; Thomas Burke, PhD; Frank Xiaoqing Liu, PhD; Rufang Xu, PhD, Vamsidhar Velcheti, MD</td>
<td>Outcomes and Health Services Research</td>
</tr>
<tr>
<td>66</td>
<td>Min Huang, PhD</td>
<td>Healthcare Resource Utilization in Patients Receiving Pembrolizumab or Standard-of-Care Chemotherapy with Previously Untreated Metastatic NSCLC</td>
<td>James Pellissier, PhD; Jane Liss, MA</td>
<td>Outcomes and Health Services Research</td>
</tr>
<tr>
<td>67</td>
<td>Karen Skinner, MPH</td>
<td>Oncology Characteristics of Patients Treated with Fulvestrant as First Hormonal Therapy for Metastatic Breast Cancer in a Real World Setting</td>
<td>Temitope O. Oluofada, PhD, MPH; Nicola Di Santio, MD; Rahul Shenoi, PhD; Sam W. Walker, PhD; Lee S. Schwartzberg, MD, FACP</td>
<td>Outcomes and Health Services Research</td>
</tr>
<tr>
<td>68</td>
<td>Amy Viyas, PhD, MS, MBA</td>
<td>University of Rhode Island Impact of Depression Treatment on Health-Related Quality of Life Among Adults with Cancer and Depression: A Population-Level Analysis</td>
<td>Zachary Badrock, MBA; Stephen Kogut, PhD, MBA</td>
<td>Outcomes and Health Services Research</td>
</tr>
<tr>
<td>69</td>
<td>Zhou Zhou, MS</td>
<td>Analysis Group Impact of Endocrine Therapy on Quality of Life of Women with HR+/HER2- Advanced Breast Cancer - A Systematic Literature Review</td>
<td>Derek H. Tang, PhD, BS Pharm; Jihan Xie, MD, PhD; Rajeev Ayyagari, PhD; Poly A. Nivashv, MD</td>
<td>Outcomes and Health Services Research</td>
</tr>
<tr>
<td>70</td>
<td>Brian Ung, PharmD</td>
<td>Celgene Corp Total Healthcare Costs and Treatment Patterns among Metastatic Pancreatic Cancer (MPC) Patients (p) Initiating First-Line (1L) on nab-Paclitaxel/Gemcitabine [nab-P+G] or FOLFIRINOX (FFX)</td>
<td>Corey Pollitter, PhD; Marshall Patel, MS, PharmD; Quanhong Ni, MS</td>
<td>Outcomes and Health Services Research</td>
</tr>
<tr>
<td>71</td>
<td>Somrita Modak, MBBS</td>
<td>SGS Medical College &amp; Hospital A Comparative Study of Gastrointestinal Symptom Severity and its Interference with Quality of Life in Non-Gastrointestinal Cancer Patients Depending on Various Treatment Modalities</td>
<td>Harmander Singh, MD; Abhijnandhan Mukhopadhyay, Mch</td>
<td>Outcomes and Health Services Research</td>
</tr>
<tr>
<td>72</td>
<td>Li Peng, PhD</td>
<td>Cancer Hospital of China Medical University, Leizhou Cancer Hospital &amp; Institute The Prognostic Value of Uncharacterized IncRNA LDC1001035373 in Human Hepatocellular Carcinoma</td>
<td>Xiao-Qing Yuan, PhD; Wen-Ling Li, Master; Zhan-Yan Liu, Master; Hui-Fang Zhou, Master; Ya-Qing Zhang, Master; Guan-Cheng Li, PhD</td>
<td>Outcomes and Health Services Research</td>
</tr>
<tr>
<td>73</td>
<td>Anwaj El-Jawahri, MD</td>
<td>Massachusetts General Hospital Cancer Center A Multimodal Intervention to Address Sexual Dysfunction in Hematopoietic Stem Cell Transplant (HCT) Survivors: A Feasibility Study</td>
<td>Sarah Fishman, BA; Jake Vanderkilsh, NP; Lara Treager, PhD; Don Dixon, MD; Jennifer Temel, MD</td>
<td>Outcomes and Health Services Research</td>
</tr>
<tr>
<td>74</td>
<td>Sandra Flores</td>
<td>Hospital Universitario Veregno del Rocio Surrogate Endpoints in Metastatic Breast Cancer in First or Second Line Trial</td>
<td>Lala Abdel-Kader Martin; Maria Dolores Vega Coca; Javier Bautista Paloma</td>
<td>Outcomes and Health Services Research</td>
</tr>
<tr>
<td>75</td>
<td>Yanli Hao, PhD</td>
<td>Acetique Analytics Comparison of Clinical Outcomes among Chelated vs. Non-Chelated Patients with Myelodysplastic Syndromes: A Real World Medicare Database Study</td>
<td>Alex Fu, PhD; Austin Cox, MPH; Ying Gao, PhD; Zhiyi Li, MBA, MA; Becky Home, MPH; Jackson Tang, MSc; Brian Elliott, MD; Carole Paley, MD</td>
<td>Outcomes and Health Services Research</td>
</tr>
<tr>
<td>76</td>
<td>Alexandra Zaleta, PhD</td>
<td>Cancer Support Community Refining a Validated Distress Screening Tool for Caregivers of Cancer Patients in a Community-Based Sample</td>
<td>Margaret Langenac, PhD; Melissa Miller, PhD; Mitch Golan, PhD; Victoria Kennedy, LCSW; Keyle Miller, BS; Joanne Busaghi, PhD</td>
<td>Outcomes and Health Services Research</td>
</tr>
<tr>
<td>77</td>
<td>Melissa F. Miller, PhD, MPH</td>
<td>Cancer Support Community The Psychosocial Impact of Lung Cancer-Related Stigmata: Findings from the Cancer Experience Registry</td>
<td>Joanne Buzaglo, PhD; Alexandra Zaleta, PhD; James Johnson, MPH, MPH; Janne Catoletto, RN, PhD, FAAN; Linda House, RN, BSN, MSW</td>
<td>Outcomes and Health Services Research</td>
</tr>
<tr>
<td>78</td>
<td>Dominic Plon, MA</td>
<td>Jason Scientific Affairs, LLC Refill Gaps and Dose Reductions in Patients with Prostate Cancer and Visceral Metastases Treated with Abiraterone Acetate plus Prednisone or Enzalutamide</td>
<td>Ajay S. Bhat, PhD; Bruno Emont, MSc; Marie-Helene Lefebvre, MA; Patrick Leclaire, MA</td>
<td>Outcomes and Health Services Research</td>
</tr>
<tr>
<td>79</td>
<td>Echo L. Warner, MPH</td>
<td>Huntsman Cancer Institute at the University of Utah Supporting Adolescents and Young Adults (AYAs) with Cancer: Oncology Provider Perceptions of AYAs’ Unmet Needs</td>
<td>Bryan Fowlie, MPH; Samantha Pannier; Douglas Fai, MD; Hiday Sparraker-Petram; MD; R. Lor Randall, MD; Anne C. Kirkhoff, PhD, MPH</td>
<td>Outcomes and Health Services Research</td>
</tr>
<tr>
<td>80</td>
<td>Fatemeh Zarghami, MD, MPH</td>
<td>Virginia Polytechnic Institute and State University Analysis of the Conceptual Models Developed by Stakeholders Participating in the SEED Method for Improving Lung Cancer Outcomes in Martinsville/Henry County, Virginia</td>
<td>Carlos Rafael, PhD, RD</td>
<td>Outcomes and Health Services Research</td>
</tr>
<tr>
<td>Poster #</td>
<td>Primary Author and Institution</td>
<td>Title</td>
<td>Co-Authors</td>
<td>Category</td>
</tr>
<tr>
<td>----------</td>
<td>-------------------------------</td>
<td>-------</td>
<td>------------</td>
<td>----------</td>
</tr>
<tr>
<td>81</td>
<td>Vineeta Agarwala, MD, PhD</td>
<td>The NCCN-Flatiron Outcomes Database: Collaborative Evidence Development and Quality Improvement in Oncology</td>
<td>Benjamin Bimbam, MD; James Gippetti, MS; Laini Talcott, MHA; Joshua Kraut; Bryan Bowser; Joseph Delpado; Caroline Nightengale; Michael Lorr; Nathan Nassbaum, MD; Dominique Connolly, RN; MA; James Martinez, MS; Katie Dorius, PhD; Kristen Fesselle, PhD; Joan McClure, MS; Lyn Fitzgerald, MJ; Robert Carbon, MD; Amy Abemethly, MD, PhD</td>
<td>Outcomes and Health Services Research</td>
</tr>
<tr>
<td>82</td>
<td>Margaret McCluskey, MD, MS</td>
<td>Radiographic Imaging Test Utilization Among Metastatic Lung Cancer Patients During First EGFR TKI Treatment</td>
<td>Mindy Cheng, MD, PhD; Yu-Chen Lee, Msc; I-Ning Cheng, MD; Frank Convis, MD; Nengian Zhao; Sid Scudeller, MD</td>
<td>Outcomes and Health Services Research</td>
</tr>
<tr>
<td>83</td>
<td>Mary Victoria Rios Perez, MD</td>
<td>Auranofin Prevents Progression of Human Pancreatic Ductal Adenocarcinoma</td>
<td>David Rolle, MD; Bing Bing Dai, PhD; Yu’an Kang, MD, PhD; Xinlin Li, MD; PhD; Michael Pratt, BS; Jason B. Fleming, MD</td>
<td>Pre-Clinical Oncology</td>
</tr>
<tr>
<td>84</td>
<td>Mary Katherine Murray, MD, FACs</td>
<td>Evaluation of Early Referral Patterns for Lymphedema Management Following Axillary Dissection in Breast Cancer Patients</td>
<td>Brenda Runion, PT, MBG, DPT, CCCE</td>
<td>Quality Improvement</td>
</tr>
<tr>
<td>85</td>
<td>Laura Bray-Hannin, MA</td>
<td>Applying Lean Principles and Predictive Analytics to Improve Patient Access, Decrease Wait Time, and Reduce Healthcare Delivery Costs at UCSF Helen Diller Family Comprehensive Cancer</td>
<td>Mohan Girdharidasav; Marisa Quinn, RN, MBA</td>
<td>Quality Improvement</td>
</tr>
<tr>
<td>86</td>
<td>Alexandra K. Brennan, BS</td>
<td>Lumphectomy Cavity Clip Placement and Improved Radiation Therapy Outcomes in a Military Population</td>
<td>Melinda J. Weiblen, BS; Wmnedth M. Wong, DO</td>
<td>Quality Improvement</td>
</tr>
<tr>
<td>87</td>
<td>Amanda Samzienko, MBA, MPM, SSBB</td>
<td>Exam Clinic to Chemotherapy Care Coordination – “Working as a Multidisciplinary Team to Create an Exceptional Patient Experience”</td>
<td>Penny Moore, MSN, RN, OCIN, NEA-BC</td>
<td>Quality Improvement</td>
</tr>
<tr>
<td>88</td>
<td>Karina Claghorn, MS, CSO, LDN</td>
<td>Harnessing the EMR to Improve Coordination of Care for Head and Neck Cancer Patients: A Team Approach</td>
<td>Audrey Caspar Clark, MS, RD, CSO, LDN; Margaret Runnel, BSN, RN, MHA, OCIN; Tracy lauttenbach, MSW; LCINW</td>
<td>Quality Improvement</td>
</tr>
<tr>
<td>89</td>
<td>YuQian Liu, PharmD</td>
<td>Impact of Pharmaceutical Outreach and Intervention on Tyrosine Kinase Inhibitor (TKI) Adherence and Compliance to Response Testing in Patients with Chronic Myeloid Leukemia (CML)</td>
<td>Sam Luo, PharmD; Hala Makajani, PharmD; Anne Kargellige, PharmD, MPhD; Steve Cuts, PharmD</td>
<td>Quality Improvement</td>
</tr>
<tr>
<td>90</td>
<td>Joanna Grace Mayo Manzano, MD</td>
<td>Evaluating the Impact of an Oncology-Hospitalist Model of Inpatient Care on Unplanned 30-Day Readmissions Among Patients with Lung Cancer</td>
<td>Heather Yen Lin, MD, PhD; Anne Park, MSMS, MPH; Suyu Liu, PhD; Joseph Hixen, MD, FACP</td>
<td>Quality Improvement</td>
</tr>
<tr>
<td>91</td>
<td>Kathleen J. Tosti, PhD</td>
<td>The Consumer Assessment of Healthcare Providers and Systems (CAHPS®) Cancer Care Survey: Administration and Sampling Recommendations</td>
<td>Christian Evensen, MS; Sarah Jenkins, MS; Sue Vaschar, MPhD; Timothy Bebee, BS; San Keller, PhD; Steven Garfinkel, PhD</td>
<td>Quality Improvement</td>
</tr>
<tr>
<td>92</td>
<td>Christine Brezina Weldon, MBA</td>
<td>Metastatic Breast Cancer Quality Improvement: Pre-Implementation Data From the 4R in Oncology Project</td>
<td>Valerie M. Nelson, MD; Jennifer Steels, MD; Jonathan B. Strauss, MD, MBA; Dylan Sarrazinwitz, MD; Al B. Benson, MD; Sarah M. Friedwald, MD; William J. Gradishar, MD; Melissa A. Simon, MD, MPH; Julia R. Trosman, PhD, MBA</td>
<td>Quality Improvement</td>
</tr>
<tr>
<td>93</td>
<td>Julia Rachel Trosman, PhD, MBA</td>
<td>Supportive Oncology Care - An NCCN Online Educational Series</td>
<td>Betty Roggenkamp, BA; Stephanie Merce Berkoff, RN, OCIN, MSN, BSN, BA; Amy Schu, MSH, CHCPA; Patricia A. Robinson, MD; Frank Penado, PhD; Sofia F. Garcia, PhD; Teresa Lills, PhD; Rosa Berardi, BA; Javier Mariscas, MD; James Gerhart, PhD; Paraperaft Kholaisa, MD; Shelly Lu, MD; Lauren Weiers, MD; William Dale, MD, PhD; Sheetal Matha Kincher, MD; Carol Newsom, RN; Carol A. Rosenberg, MD; Catherine Desamand, MD; Christine Weldon, MBA</td>
<td>Quality Improvement</td>
</tr>
<tr>
<td>94</td>
<td>Lauren Nicole Wernsing, BSN, RN, CPHON</td>
<td>Multidisciplinary Approach to Grading Infusion Related Reactions in an Oncology Treatment Unit</td>
<td>Angela Oiler-Pins, DNP, MBA, RN; Lorraine Aquino Perez, MSN, ARNP, AGNP-BC, AOCNP; Rohanm Perez, BSN, RN; Gloria Campos, MSIE</td>
<td>Quality Improvement</td>
</tr>
<tr>
<td>95</td>
<td>Doni Klemanski, DNP, CNP</td>
<td>Development of Cancer Survivorship Clinical Dashboard</td>
<td>Maryam Lustberg, MD, MPH</td>
<td>Quality Improvement</td>
</tr>
<tr>
<td>96</td>
<td>James Gippetti, MS</td>
<td>Real-World Rates of Chemotherapy Use Near the End of Life (EOL) in Cancer Patients</td>
<td>Vineeta Agarwala, MD, PhD; Joshua Kraut; Cindy Rerol; Dylan Peterson; Kristen Fesselle, PhD; Amy Abemethly, MD, PhD</td>
<td>Quality Improvement</td>
</tr>
<tr>
<td>97</td>
<td>Kathleen Rogers, BS, CNP</td>
<td>Best of Both Worlds: Integrative and Consultative Survivorship Care in a Comprehensive Breast Center</td>
<td>Steve Kastler, MHA, MBA; Doni Klemanski, DNP, CNP; Heidi Basinger, BSN; Julia Garret, BSN, CNP; Denise Schimming, BSN, CNP; Felisha Lynn, MSW, Maryam Lustberg, MD, MPH</td>
<td>Quality Improvement</td>
</tr>
</tbody>
</table>
When You’re on a Mission—Shoot for the Moon

At Duke we leverage the totality of minds and resources into our all-out effort to end cancer. That means more cross-pollination, more knowledge exchanged and more third- and fourth-order connections to deliver electrifying insights and open new avenues of research, prevention and treatment.

“The Cancer Moonshot is a mission, and we all #CanServe.”

–Former Vice President Biden

Duke Cancer Institute

Research, education, patient support, and advocacy to end mesothelioma.

One mission. One cause. One community.

The Mesothelioma Applied Research Foundation is the only 501(c)(3), charity nonprofit organization working to eradicate mesothelioma and ease the suffering caused by this cancer.

curemeso.org®
TELL CANCER TO TAKE A HIKE!

- Customized survivor/caregiver retreats for your patients in the Colorado Rockies
- Hiking in Rocky Mountain National Park
- Cancer-fighting gourmet meals
- Sponsorships available
- See us at Booth A6

Live By Living, a 501(c)(3), has been connecting cancer survivors and caregivers with nature and one another since 2009
www.livebyliving.org  |  303-808-2339  |  dsm@livebyliving.org

Lung MATCH
Lung Cancer Alliance

Helping you find and understand the personalized treatment options that are right for you.

WWW.LUNGMATCH.ORG

- Professionally trained specialists
- Easy online platform
- Full panel molecular testing
- Personalized treatment and trial packages
Your patients with lung cancer have questions. We can help.

LUNGevity has information and support that patients and caregivers need to make informed healthcare decisions. Visit www.LUNGevity.org to learn more.

Lung Cancer 101 is a comprehensive medically vetted online guide to understanding how lung cancer develops, how it can be detected, treatment options and what to expect. Download tips, booklets, and informational videos.

Experts Blog includes clear discussions about the latest developments in research and what they mean for patients.

Lung Cancer Navigator mobile app helps patients manage their healthcare. Lung Cancer HELPLine is a toll-free support service answered by oncology social workers. Call 844-360-LUNG.

Online Survivor and Caregiver Resource Centers help patients live well with lung cancer, and provide tip sheets with questions for visits with one’s medical team.

LifeLine matches patients and caregivers to mentors who have had similar experiences, for personalized one-on-one support. Clinical Trial Ambassadors are volunteers available to offer information about their personal experiences with clinical trials to fellow lung cancer patients.

Lung Cancer Support Community message boards provide patients and caregivers with peer-to-peer support and information.

HOPE Summits are conferences designed specifically for patients, survivors, and caregivers to hear from medical experts, inspirational speakers, and each other. These unique meetings build communities of hope and support for people at all stages of a lung cancer diagnosis.

About LUNGevity Foundation

LUNGevity Foundation is firmly committed to making an immediate impact on increasing quality of life and survivorship of people with lung cancer by accelerating research into early detection and more effective treatments, as well as by providing community, support, and education for all those affected by the disease. For more information, please visit www.LUNGevity.org.

BOLD IDEAS.
BOLD INNOVATIONS.

For more than 40 years, Seattle’s Fred Hutchinson Cancer Research Center has led the way in bold, lifesaving discoveries, beginning with our Nobel Prize–winning work in bone marrow transplantation as a cure for certain blood cancers. Since then, our teams have continued to innovate, laying the groundwork for the HPV vaccine, building the world’s premier cancer prevention program, and pioneering immunotherapies to defeat cancer. Until cancer and related diseases are gone, we’ll keep innovating.

GET INSPIRED | fredhutch.org

Fred Hutch Cures Start Here®
Lung Cancer 101 is a comprehensive medically vetted online guide to understanding how lung cancer develops, how it can be detected, treatment options and what to expect. Download tips, booklets, and informational videos.

Experts Blog includes clear discussions about the latest developments in research and what they mean for patients.

Lung Cancer Navigator mobile app helps patients manage their healthcare.

Lung Cancer HELPLine is a toll-free support service answered by oncology social workers. Call 844-360-LUNG.

Online Survivor and Caregiver Resource Centers help patients live well with lung cancer, and provide tip sheets with questions for visits with one’s medical team.

LifeLine matches patients and caregivers to mentors who have had similar experiences, for personalized one-on-one support.

Clinical Trial Ambassadors are volunteers available to offer information about their personal experiences with clinical trials to fellow lung cancer patients.

Lung Cancer Support Community message boards provide patients and caregivers with peer-to-peer support and information.

HOPE Summits are conferences designed specifically for patients, survivors, and caregivers to hear from medical experts, inspirational speakers, and each other. These unique meetings build communities of hope and support for people at all stages of a lung cancer diagnosis.

About LUNGevity Foundation
LUNGevity Foundation is firmly committed to making an immediate impact on increasing quality of life and survivorship of people with lung cancer by accelerating research into early detection and more effective treatments, as well as by providing community, support, and education for all those affected by the disease. For more information, please visit www.LUNGevity.org.

LEADING THE WAY CANCER IS TREATED TODAY AND TOMORROW
The Stanford Cancer Institute (SCI) is committed to giving patients every clinical and technological advantage in the prevention and treatment of cancer. The SCI leverages the expertise of over 300 physicians and researchers working together to unravel cancer’s secrets. Stanford’s scientific focus includes cancer cell and stem cell biology, immunology, molecular imaging and genetics. Translational medicine is the cornerstone of Stanford’s cancer treatment programs, combining new advances with compassionate care and supportive services.
TAKING ON CANCER

Research innovation, cutting edge treatment options, patient-focused care — that’s the future of cancer care.

The University of Michigan Comprehensive Cancer Center is looking towards the future. Our physicians are exploring metabolomics in our labs, taking precision medicine therapies from bench to bedside, and partnering with physicians around the state to offer appropriate care at the appropriate place. It’s all part of how we empower our patients to take on cancer. Find out more at mcancer.org.

WE’RE RECRUITING...

Roswell Park Cancer Institute is seeking Radiation Oncologists to provide compassionate patient care at our growing locations throughout Western New York. These positions provide an exceptional opportunity for quality of life while still providing the fulfillment and challenge of a robust and technologically advanced department. The area is known for its beauty and many recreational activities in all four seasons. The salary and benefit package will be competitive.

Interested applicants may inquire by email to Melissa.Therrien@RoswellPark.org
We believe everyone deserves a fair shot at getting to the other side of cancer.

We are a financial lifeline for families fighting cancer nationwide.

Siteman Cancer Center has received the National Cancer Institute’s highest possible rating in cancer research.

Siteman Cancer Center

Exceptional.

St. Louis, Missouri

1-800-600-3606
siteman.wustl.edu
Looking for more information about SUSTOL?

Visit us at booth #118
Diane is one of over 700,000 patients worldwide who have used Oncotype DX to determine — with confidence — whether they could avoid unnecessary therapies and procedures, saving the healthcare system billions of dollars. In making genomics a critical part of cancer diagnosis and treatment, Oncotype DX represents precision medicine in action.
Nearly **85%** with advanced disease will relapse.

An unrelenting malignancy that went **30 years** with no major therapeutic advancements.

That's why there's **500** associates, **1** shared commitment to change the numbers for women bravely facing ovarian cancer.